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ABSTRACT OF THE DISSERTATION
The Ugly Sequestosome1: The role of SQSTM1 in autophagy and multisystem proteinopathy
by
Eugene Lee
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2018
Professor Conrad Weihl, Chair

Multisystem proteinopathy (MSP) defines a spectrum of degenerative diseases unified by TDP43 pathology that affect muscle, brain and bone. Mutations in several proteins (VCP,
p62/SQSTM1, HNRNPA2B1, HNRNPA1) can all cause MSP via impairments in autophagic
protein degradation (VCP and SQSTM1) or RNA granule dynamics (HNRNPA2B1 and
HNRNPA1). Phenotypically, MSP mutations lead to variable penetrance of several phenotypes:
Paget’s disease of the bone (PDB), rimmed vacuolar inclusion body myopathy (RV-IBM),
amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD). However, how a same
mutation of a protein can develop different diseases remains unclear. Understanding of
p62/SQSTM1 (SQSTM1) function is critical to answer this question. In this dissertation, we
provide evidence that SQSTM1 is regulated via its UBA domain ubiquitination. We find that
Keap1/Cullin3 ubiquitinates SQSTM1 at lysine 420 within its UBA domain. Substitution of
lysine 420 with arginine or disease-associated mutation of SQSTM1 disrupts its ubiquitination,
sequestering activity, and degradation. In contrast, overexpression of Keap1/Cullin3 in

x

SQSTM1-WT expressing cells increases ubiquitinated inclusion formation, SQSTM1’s
association with autophagosomes and rescues proteotoxicity.
We also provide evidence that the oligogenic inheritance of a disease associated
SQSTM1 mutation with a rare coding variant in the low-complexity domain (LCD) of the RNAbinding protein, TIA1 (p.N357S) can dictate a myodegenerative phenotypes. Deletion or
mutation of SQSTM1 along with TIA1 disease mutants synergistically impairs RNA stress
granules clearance and their dynamics. These findings demonstrate a pathogenic connection
between SG homeostasis and ubiquitin mediated autophagic degradation that defines the
penetrance of a MSP phenotype.
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Chapter 1: Introduction

1

1.1 Overview: Multisystem proteinopathy
“The Ugly Duchess” painted by Quentin Matsys around 1513 is a portrait of an old grotesque
woman holding a red rose with her wrinkled face skin and breasts. This painting had been
thought to be a satire of an old lady trying to seduce her younger lover. More than 150 years
later, one surgeon finally suggested that this woman suffered from Paget’s disease of the bone
(PDB) with deformed joints and bones. The most common genetic causes of PDB is a mutation
in p62/SQSTM1 (SQSTM1), whose function has been established in protein homeostasis.
Protein homeostasis is regulated by a complex network of chaperones, ubiquitin,
proteases, and other factors. Cellular protein homeostasis has evolved to battle with cellular
stresses including heat shock, oxidative stress, chemical stress, viral/bacterial invaders, and even
their own inevitable event, aging [1]. Protein homeostasis should be more tightly regulated in
differentiated cells since they are incapable of diluting toxic materials by mitosis.
Multisystem proteinopathy (MSP) defines inherited degenerative diseases that affect
muscle, central nervous system (CNS) and bone [2]. MSP mutations in some genes lead to a
variable penetrance of different disease phenotypes: PDB, rimmed vacuolar inclusion body
myopathy (RV-IBM), amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD).
One distinctive feature of MSP pedigrees is that patients with the same mutation and even the
same mutation within a family can have different disease phenotypes (i.e. PDB in one sibling
and ALS in another sibling). It is not surprising that MSP is mostly a late-onset disease since
aging accelerates somatic mutations and protein homeostasis collapse of all tissues. The vast
majority of MSP-affected tissues showed nucleocytoplasmic transport defect,
misfolding/aggregation of proteins, and dysfunctional protein degradation. They are accumulated
2

with ubiquitianted aggregates in the cytoplasm that contain RNA-binding proteins with lowcomplexity domain (LCD) such as TDP-43, FUS and may include autophagy related proteins
such as VCP, SQSTM1[2]. Interestingly, genes associated with MSP or related to MSP can be
distinguished into two categories: autophagic degradation proteins (VCP, p62/SQSTM1) or
RNA-binding proteins (HNRNPA2B1, HNRNPA1, TIA1, MATR3). However, how a same
mutation of a protein can cause different diseases is unclear. For example, one disease associated
SQSTM1 mutation that has been demonstrated to cause the full spectrum of MSP phenotypes
(PDB, RV-IBM, ALS and FTD) is a proline to a leucine mutation at residue 392 (P392L) in the
UBA domain [3-6]. This single mutation is the most common genetic cause of PDB but is
incompletely penetrant suggesting that other genetic or environmental factors are needed for the
phenotypic manifestation of PDB, RV-IBM, ALS or FTD. Thus, understanding a MSPassociated protein is critical to answer these two questions: how does a MSP-protein, SQSTM1,
contribute to pathogenesis of MSP? What other factors are involved in MSP pathogenicity?

1.2 Autophagy
Autophagy is a highly conserved degradative mechanism in eukaryotic cells. The term
“autophagy” means “self-eating” in Greek to describe the presence of single- or doublemembraned intracellular vesicles containing cellular compartments or organelles [7]. Under
basal condition, autophagy plays a critical role to maintain homeostasis to recycle nucleic acids,
lipids, proteins, carbohydrate, and organelles. With internal or external stress, cellular materials
or invading bacteria/virus are recognized by autophagic adaptor proteins and sequestered into
double-layered phagopores, which become autophagosomes after the membrane closure. These
autophagosomes fuse with lysosomes and their engulfed cargoes are degraded.
3

Autophagosomes formation is a rapid process but requires more than 100 proteins [8].
Briefly, a ULK/Beclin-1/VPS34 complex localizes the site of autophagosome initiation. Active
VPS34 phosphorylates the lipid to generate phosphatidylinositol 3-phosphate (PtdIns(3)P) on the
phagopore. PtdIns(3)P on the surface of phagopore is recognized by ATG12, which directly
interact with ATG16L1. ATG16L1 and ATG12-ATG5 to form a complex that activates ATG7
and ATG3. Together with ATG16L1/ATG12/ATG5, ATG3 and ATG7 covalently conjugates
phosphatidylethanolamine (PE) to LC3-I, which is a maturation form of LC3 after proteolytic
cleavage at its c-terminus. Lipidated LC3 known as LC3-II is attached on membranes, allowing
cargoes uptake upon interaction with several autophagic adaptor proteins and the membrane
closure. While autophagic structure grows, various cellular sources such as the endoplasmic
reticulum (ER), Golgi, recycling endosomes, mitochondria, and plasma membrane will supply
autophagic membrane materials [9].

1.3 The role of SQSTM1 in autophagy
In addition to the identification of MSP-associated autophagy genes, autophagy has been linked
to MSP since tissue-specific ablation of autophagy genes in mice and other models mimics a key
pathological feature of MSP: the accumulation of ubiquitin-positive inclusion bodies in the
cytoplasm [10-13]. Since autophagy genes knock-out mouse models (ATG5-/- or ATG7-/- mice)
die soon after birth, neural-cell-specific ATG5-/- mice was generated. In this mouse model,
SQSTM1-positive ubiquitinated proteins were accumulated in central nervous system. In
addition, they showed motor and behavioral deficits, suggesting that the autophagy in basal level
maintain protein homeostasis to prevent from neurodegeneration [10]. In muscle-specific ATG7/- mice, SQSTM1-positive ubiquitinated proteins and vacuolar structures were accumulated in
4

muscle fibers together with disrupted sarcomere and other muscle structures, indicating that
these mice have myopathy [13].
Autophagy can be a selective degradative process via the utilization of various
autophagic adaptor proteins. SQSTM1 is one of such autophagic adaptor proteins, which
selectively recognize ubiquitinated cargoes and deliver them to growing autophagosomes for
their degradation. SQSTM1 had been initially identified as a polyubiquitin shuttling protein to
the 26S proteasome [14]. However, two types of cytoplasmic SQSTM1 inclusions (SQSTM1
bodies) with ubiquitin aggregates were consistently observed: small membrane-less bodies and
larger bodies with autolysosomes (Figure1) [15-17]. These observations suggest the role of
SQSTM1 in autophagy. More specifically, SQSTM1 directly binds to ubiquitinated protein
aggregates via its UBA domain and sequesters them into inclusion bodies via its PB1 domain.
SQSTM1 also interacts with autophagosomes via its LC3-interacting (LIR) motif [16, 18].
Depletion of SQSTM1 in cell, mice and Drosophila models leads to the accumulation of soluble
ubiquitinated proteins without the formation of inclusion bodies, suggesting that SQSTM1 is
required for the formation and degradation of inclusion bodies in the cytoplasm [11, 12, 16, 18].
Cargo trafficking to autophagosomes is not solely driven by one autophagic adaptor
protein alone. Different autophagic adaptor proteins cooperate to each other to select specific
cargoes [9]. For example, SQSTM1 teams up with NBR1 to recognize aggregated proteins [19].
NDP52 and optineurin (OPTN) aid SQSTM1 to get rid of invading bacteria [20-22]. Depletion
of a certain autophagic adaptor protein does not always guarantee the impairment of a selective
autophagic process, suggesting the complementary but selective function of autophagic adaptors.
However, a regulatory mechanism for autophagic adaptors is not yet well-established.

5

Figure 1. The very first observed SQSTM1 body [17].

6

1.4 Ubiquitination and ubiquitin-binding proteins
Ubiquitin is a versatile modification protein that controls a various cellular process. A protein
degradation function was the first identified function of ubiquitin, but it has been expanded to
various cellular functions including inflammation, DNA repair, signal transduction, endocytosis
and autophagy [23, 24]. Covalently binding of ubiquitin to a target protein requires E1/E2/E3
enzymes. E1 enzymes (two have been identified in human) activate ubiquitin to form an E1ubiquitin thioester in an ATP-dependent manner. They are transferred to E2 enzymes (~40 have
been identified in human) to form an E2-ubiquitn thioester. Finally, E3 ligases (~600 have been
identified in human) interact with the E2-ubiquitin thioester and a target protein. E3 ligases
catalyze them to form the isopeptide bond between the c-terminal glycine of ubiquitin and lysine
residue of a target protein. Deubiquitinating enzymes (DUB; ~100 have been identified) remove
tagged ubiquitins from the target proteins.
The modification by ubiquitin (referred to as ubiquitination) on a target protein can be
varies from a single molecule attachment (monoubiquitiantion), several single attachments
(multiple monoubiquitination) to a ubiquitin chain attachment (polyubiquitination).
Polyubiquitination occurs when a glycine residue of ubiquitin repeatedly links to one of seven
lysine residues (K6, K11, K27, K29, K33, K48, and K63) within a neighboring ubiquitin. The
function of each mono- and poly-ubiquitination chain has not been well-studied, but it is
believed that different ubiquitin chains can dictate various cellular functions [25, 26]. K48-linked
polyubiquitination is a classic example that targets a protein to the proteasome for their
degradation. The multisubunit 26S proteasome is a cylinder complex that recognizes, unfolds
and transfers polyubiquitinated proteins into its hollow core where the substrates are catalyzed
7

into small peptides. In contrast, K6-linked polyubiquitination does not destabilize its target
protein or increase its abundance upon proteasomal inhibition, suggesting its proteasomeindependent function. K63-linked polyubiquitination is known as a preferential signal of protein
aggregates for their autophagic/lysosomal degradation. Also, K63-linked polyubiquitinatoin can
increase interaction of a target protein with other proteins while monoubiqutination can inhibit
the interaction.
Along with different ubiquitin conjugation systems, the specificity of ubiquitin signaling
is also achieved by post-modifications on ubiquitin molecules and/or multiple ubiquitin-binding
proteins [23]. Ubiquitin-binding proteins contain ubiquitin-binding domains such as UIM, CUE,
UBAN, and UBA domains, which non-covalently bind to a hydrophobic patch (Ile 36 or Ile44
patch) of ubiquitin. Ubiquitin-binding proteins are frequently regulated by its ubiquitination. For
example, monoubiquitination of a UIM-domain containing protein, eps15 alters its binding to
ubiquitin and disturbs its function during endocytosis [27, 28]. Thus, the combinational use of
ubiquitination and ubiquitin-binding proteins endlessly but selectively expands cellular
regulatory modules.
The collaborative practice of various ubiquitin chains and ubiquitin-binding proteins may
also contribute to the selective autophagy. Mitophagy is the best example that the outer
membrane of damaged mitochondria can be tagged with K6, K11, K48, and K63-linked
polyubiquitiantion catalyzed by Parkin E3 ligase in vivo and in vitro in different cells [29]. The
ubiquitin chains are recognized by several ubiquitin-binding autophagy adaptors such as
SQSTM1, OPTN, NBR1, NDP52, and Tax1-binding protein1. However, which type of ubiquitin
chain is specifically recognized by autophagic adaptors remains elucidated. Recent studies
suggested that post-translational modification regulates the preferential binding of autophagic
8

adaptors during selective autophagy. Two different studies demonstrated that TBK1-mediated
phosphorylation within/adjacent to ubiquitin-binding domain (UBAN) of OPTN selectively
increases its binding affinity to K48 and K63-linked polyubiquitin chains during mitophagy [30,
31]. Similarly, casein kinase2 phosphorylates SQSTM1’s UBA domain, increasing its binding
affinity to K63-linked polyubiquitin in vitro [32].

1.5 Regulation of autophagic adaptor proteins by
ubiquitination
Autophagic adaptor proteins directly associate with ubiquitinated proteins via its ubiquitinbinding domain. Accumulating evidence supports that ubiquitination also regulates the function
of autophagic adaptor proteins. For example, K48-linked ubiquitination of the autophagic
adaptor OPTN by HACE1 increases its association with SQSTM1 and enhances autophagic flux
[33]. Also, several studies suggest that ubiquitination of SQSTM1 modulates its functions.
RPN26 ubiquitinates SQSTM1’s UBA domain at the ER membrane leading to an increase in
SQSTM1’s capture of ubiquitinated endosomes [34]. However, it is not clear which lysine within
SQSTM1’s UBA domain is ubiquitinated by RPN26. During xenophagy, RNF166 catalyzes
K33-lnked ubiquitination of SQSTM1 and recruits SQSTM1 and another autophagic adaptor,
NDP52 to ubiquitinated bacteria [35]. RNF166 may target multiple lysine sites within different
domains of SQSTM1 including K91 in the PB1 domain. Parkin and TRIM21 also ubiquitinate
SQSTM1’s PB1 domain [36, 37]. Parkin catalyzes ubiquitination of K13, promoting SQSTM1’s
degradation. TRIM21 ubiquitinates SQSTM1 at K7 within the PB1 domain, abrogating
SQSTM1’s oligomerization and sequestering activity. Other E3 ligase, NEDD4 is also reported
to ubiquitinate SQSTM1 via its PB1 domain, affecting SQSTM1 body formation [38]. Notably,
9

an E2 complex, UBE2D2/UBE2D3 catalyzes ubiquitination at K420 within SQSTM1’s UBA
domain [39]. This E2 ligase complex directly interacts with SQSTM1 via residues adjacent to the
LIR motif.

1.5 The domain of SQSTM1 and its function
SQSTM1 directly interacts with another E3 ligases complex, Keap1/Cullin (Cul3) to regulate
cell signaling pathways via its Keap1-interacting motif (KIR) [40-42]. Cul3 is one of CullinRING E3 ligases, which may need an E3 ligase adaptor to catalyze its substrate. One of such E3
ligase adaptors is Keap1, which interacts with Cul3 via its BR-C, ttk and bab (BTB) domain at
the N-terminus [43]. The most well-established substrate of Keap1/Cul3 complex is a
transcription factor NF-E2 p45-related factor 2 (Nrf2). In basal level, the Kelch domain of Keap1
recognizes the DLG and ETGE motifs of Nrf2. Consequently, Nrf2 is ubiquitinated by
Keap1/Cul3 complex and delivered for proteasomal degradation. However, upon the generation
of reactive oxidative stress (ROS) or electrophile in cells, the Keap1 binding to Nrf2 is
destabilized. Stabilized Nrf2 enters the nucleus to activate the expression of genes regulated by
antioxidant response elements (AREs) [44]. Several studies demonstrated that SQSTM1
sequesters Keap1 into aggregates under conditions of autophagic inhibition [40-42, 45]. This
SQSTM1-Keap1 interaction also disturbs Keap1 interaction with Nrf2 and subsequently
diminishes Cul3-catalyzed ubiquitination on Nrf2. Thus, it allows Nrf2 to activate AREs genes.
The UBA domain mediates several functions including sequestering activity, ubiquitin
binding, and self-dimerization. UBA domain dimerization inactivates ubiquitin binding since it
shares interfaces for dimerization and ubiquitin binding [46]. Phosphorylation of the UBA
domain disrupts this self-dimerization and increases its binding affinity to ubiquitin [32, 47].
10

Similarly, a purified SQSTM1 carrying the K420R mutation abolishing its ubiquitination along
with an E409K mutation, which destabilizes the UBA dimerization increased poly-ubiquitin
association in vitro, as compared to purified SQSTM1-WT. A purified ubiquitinated SQSTM1WT also bound more poly-ubiquitin than unmodified SQSTM1-WT in vitro [39].
There is accumulating evidence that the oligomerization of autophagic adaptor proteins is
critical for recognizing polyubiquitnated protein aggregates and interacting with phagophores
[48-51]. Autophagic adaptor protein in yeast, Cue5 (human homolog Tollip) oligomerizes via its
UBA domain and this oligomerization process allows its ubiquitinated aggregates to be degraded
via autophagy, not via the proteasome [48]. However, a proteasomal protein, Dsk2 (human
homolog UBQN2) does not self-associate despite the presence of its UBA domain and
ubiquitinated aggregates accumulate in these cells.
The formation and degradation of ubiquitinated protein aggregates or organelles require
SQSTM1’s oligomerization [16, 52]. The oligomerization of SQSTM1 is required for
sequestering damaged mitochondria after Parkin catalyzes K63-linked polyubiquitination on
them (Narendra et al., 2010). This sequestering activity is mediated by SQSTM1’s UBA domain
and PB1 domain that regulates SQSTM1’s self-association [51]. This self-association of
SQSTM1 is necessary for the formation of a filamentous SQSTM1 scaffold that then allows for
the interaction with LC3 and development of phagophore membrane [53]. The deletion of either
the PB1 or UBA domains disrupts the self-association of SQSTM1 and reduces cell viability
against proteotoxicity [16]. In addition, the high-ordered SQSTM1 structure can be altered in
presence of different types of ubiquitin [50, 51, 54]. SQSTM1 filaments are fragmented in the
presence of polyubiquitin [51]. Recently, Zaffagnini and colleagues demonstrated that SQSTM1
spontaneously oligomerizes with polyubiquitin in vitro (Zaffagnini et al., 2018). Interestingly,
11

polyubiquitin and SQSTM1 respectively have different dynamics in vitro, suggesting that
SQSTM1 oligomer is a dynamic high-ordered structure but may change its dynamics in presence
of ubiquitin.

1.6 MSP disease aspect of SQSTM1
Dominantly inherited deletion or missense mutations of SQSTM1 are predominantly within its
UBA domain in several degenerative diseases, including PDB, ALS, FTD, and RV-IBM [55].
The common pathological feature among these different tissues is the accumulation of
ubiquitin/SQSTM1-positive protein aggregates. However, how SQSTM1 mutations contribute to
pathogenesis is not clear but disrupted ubiquitin binding in vitro may explain it. For example,
purified SQSTM1-M404V and SQSTM1-G425R proteins diminished ubiquitin binding in vitro
[56]. SQSTM1 mutations are recently identified in KIR motif and LIR motif from PDB and ALS
patients. These KIR disease mutants decreased the interaction with Keap1 while LIR disease
mutants diminished LC3 binding [57, 58].
The most common genetic cause of PDB is SQSTM1-P392L mutation in the UBA
domain. This mutation has been identified to cause all other MSP-spectrum diseases: RV-IBM,
ALS, and FTD [3-6]. However, this single point mutation showed incomplete penetrance with all
these MSP diseases, suggesting other genetic or environmental factors are involved. One study
showed that transgenic mice co-expressing SQSTM1-P392L mutation along with measles virus
nucleocapsid gene developed PDB phenotypes and PDB patients with SQSTM1-P392L mutation
also carry measles virus nucleocapsid gene, suggesting that this measles virus gene may dictate
bone-specific phenotypes of SQSTM1 diseases [59]. However, what dictates other SQSTM1associated disease phenotypes such as RV-IBM, ALS, and FTD still remains unclear.
12

1.7 TIA1 and stress granules
The accumulation of RNA-binding proteins such as TDP-43 in cytoplasmic inclusion bodies is
one of distinguished features of MSP [2]. In addition, several MSP mutations have been
identified in low-complexity domain (LCD) of RNA-binding proteins such as TDP-43, FUS,
HNRNPA2B1, TIA1, etc [60-65]. The MSP disease mutation-clustered LCD domain contains
repeats mostly enriched for glycine and uncharged polar amino acids, which are intrinsically
disordered [66]. Recent findings suggest that multivalent weak interactions between different
LCD domains mediate liquid-liquid phase separation (LLPS) of membrane-less organelles such
as stress granules (SGs) between soluble and liquid-droplet states [67, 68]. When LCD domaincontaining proteins undergo LLPS, these proteins demix from homogenous solutions and
separate into two phases: dense phase and dilute phase to form liquid droplets. However, the
LCD domain mutations or/and stress conditions promote LLPS and convert the proteins into
fibers.
SGs are dynamic membrane-less organelles containing untranslated mRNA, RNAbinding proteins and other initiation factors [68, 69]. SGs are evolutionally conserved in multiple
organisms and may serve several protective roles against cellular stress such as viral infection,
oxidative stress, heat shock, and proteasomal/autophagic inhibition, etc [70]. During the
translation inhibited by those stresses, mRNA and RNA-binding proteins are stalled and
assemble as SGs. Upon cellular stress dissipation, SGs disassemble into translating mRNA and
RNA-binding proteins to re-initiate the translation. Interestingly, MSP-associated mutations in
LCD domain of RNA-binding proteins alter their biophysical properties and increase their
fibrilization via LLPS, impairing SGs clearance. TIA1, a key component of SGs, is one of such
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examples. Dominantly inherited TIA1 mutations within its LCD domain manifest MSP
phenotypes including ALS/FTD and distal myopathy termed Welander distal myopathy [60, 61].
These TIA1 mutations promote LLPS and increase its fibrilization. TIA1 aggregates within SGs
along with TDP-43 and impairs the clearance of SGs.
Autophagy has been linked to SGs homeostasis. Recent studies show that SGs clearance
is impeded in autophagy-deficient or autophagy-inhibited cells. In these studies, they also
showed that a MSP-associated protein, VCP may be required for the clearance of SGs. VCP is a
ubiquitin segregase that mediates autophagic degradation of ubiquitinated proteins along with its
co-factors. VCP is the first identified MSP-associated protein that causes RV-IBM, ALS, FTD
and/or PDB. SGs clearance is impaired in VCP-depleted cells or VCP disease-mutations carrying
cells. Recent study showed that another MSP-associated protein, SQSTM1 accumulates within
SGs along with FUS disease-mutants in autophagy-deficient cells [71]. After heat shock or other
SG inducers treatment, SQSTM1 is recruited to SGs containing misfolded proteins [72, 73].
However, the mechanism of SGs clearance is still unclear.
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Chapter 2: The Regulation of
p62/SQSTM1 via UBA domain
ubiquitination
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2.1 Abstract
p62/SQSTM1 (SQSTM1) is a scaffolding protein that facilitates the formation and degradation
of ubiquitinated aggregates via its self-interaction and ubiquitin binding domains. The regulation
of this process is unclear but may relate to the post-translational modification of SQSTM1. In the
present study, we find that Keap1/Cullin3 ubiquitinates SQSTM1 at lysine 420 within its UBA
domain. Substitution of lysine 420 with an arginine diminishes SQSTM1 sequestration and
degradation activity similar to that seen when the UBA domain is deleted. Overexpression of
Keap1/Cullin3 in SQSTM1-WT expressing cells increases ubiquitinated inclusion formation,
SQSTM1’s association with LC3 and rescues proteotoxicity. This effect is not seen in cells
expressing a mutant SQSTM1 that fails to interact with Keap1. Interestingly, SQSTM1 disease
mutants have diminished or absent UBA domain ubiquitination. These data suggest that the
ubiquitination of SQSTM1’s UBA domain at lysine 420 may regulate SQSTM1’s function and
be disrupted in SQSTM1 associated disease.
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2.2 Introduction
Autophagic degradation can be a selective process targeting distinct cargoes via autophagic
receptor proteins [74]. p62/SQSTM1 (SQSTM1) is an autophagic receptor that interacts with
ubiquitinated cargo via its ubiquitin association (UBA) domain and recruits them via its LC3interacting motif into the growing autophagosome membrane [11, 16, 18]. Autophagic
degradation of ubiquitinated proteins requires SQSTM1 to sequester them into inclusion bodies.
This property is mediated by SQSTM1’s UBA domain but also via a PB1 domain that facilitates
homo-oligomerization [16, 51, 53].
The oligomerization of SQSTM1 may serve several different roles in both inclusion body
formation and autophagy. For example, SQSTM1 oligomers may organize along with
ubiquitinated proteins sequestering them into inclusions [16]. In addition, SQSTM1 forms
filamentous structures via its PB1 domain that may serve as a site for phagophore membrane
development [53]. Interestingly, SQSTM1 filaments are fragmented in the presence of
polyubiquitin [51]. This fragmentation is mediated via SQSTM1’s UBA domain and suggests
that higher-ordered oligomeric SQSTM1 structures may dynamically change in the setting of
ubiquitin.
Consistent with SQSTM1’s role in the handling of ubiquitinated protein aggregates,
dominantly inherited missense or deletion mutations within SQSTM1’s UBA domain are
associated with degenerative diseases including Paget’s disease of the bone (PDB), amyotrophic
lateral sclerosis (ALS), fronto-temporal dementia and more recently inclusion body myopathy
[55, 75]. The common pathogenic feature among these disparate tissues is the accumulation of
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SQSTM1 aggregates and ubiquitinated inclusions. How SQSTM1 mutations contribute to
disease pathogenesis is unclear but may relate to diminished ubiquitin binding activity [76].
The post-translational modification of SQSTM1 has been demonstrated to regulate its
function. Phosphorylation at one of two different serines within SQSTM1’s UBA domain
enhances its association with ubiquitinated proteins promoting sequestering activity and rescue
from proteotoxic stress [32, 47]. Ubiquitination of SQSTM1 also occurs. Mass spectrometry
approaches have identified multiple ubiquitination sites on SQSTM1 that include lysine residues
within the PB1 and UBA domains [36, 77].
Ubiquitination of SQSTM1 can also modulate its function. Recently, studies identified
ubiquitin ligases that depending upon their site of ubiquitination inhibited or facilitated
SQSTM1’s function [34, 35, 37]. The E3 ubiquitin ligase TRIM21 ubiquitinates SQSTM1 at
lysine 7 within it PB1 domain. This ubiquitination abrogates SQSTM1 oligomerization thus
inhibiting SQSTM1’s sequestration activity [37]. SQSTM1 is also ubiquitinated within its UBA
domain by the E3 ligase RNF26 although the exact residue in the UBA domain was not
determined. This ubiquitination event was proposed to enhance SQSTM1’s interaction with other
ubiquitin adaptors such as, TOLLIP, thus facilitating vesicular cargo sorting [34]. In addition,
RNF166 ubiquitinates SQSTM1 at residues K91 and K189 [35]. Interestingly, these events
involve atypical ubiquitin chains that are K29- and K33-linked. RNF166 mediated ubiquitin
ligase activity facilitates SQSTM1’s role in the xenophagic degradation of intracellular bacteria
[35].
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SQSTM1 also associates with E3 ligases to regulate cell signaling pathways. Keap1 is an E3
ligase adaptor that contains a BR-C, ttk and bab (BTB) domain at its N-terminus, which mediates
interaction with Cullin3 (Cul3) [43]. One substrate of the Keap1/Cul3 complex is Nrf2. When
Keap1 is destabilized by oxidative stress, Nrf2 stabilizes and translocates to the nucleus where it
activates the expression of genes regulated by antioxidant response elements [44]. Several
studies demonstrate that SQSTM1 binds to Keap1; sequestering it into aggregates under
conditions of autophagic inhibition [40-42]. This SQSTM1-Keap1 interaction titrates Keap1
away from Nrf2, stabilizing Nrf2 by decreasing Cul3 mediated ubiquitination and allowing Nrf2
mediated activation of the antioxidant response pathway.
In this thesis dissertation work, we find that SQSTM1 is ubiquitinated at lysine 420
within its UBA domain. This ubiquitination is mediated by the Keap1/Cul3 E3 ligase complex.
Moreover, mutation of lysine 420 or disease mutations within SQSTM1’s UBA domain affect its
ubiquitination and diminish its sequestration activity. The ubiquitination of ubiquitin binding
proteins such as SQSTM1 is emerging as a novel regulatory mechanism for autophagic adaptor
proteins.
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2.3 Material and Methods
Reagents and antibodies
N-Etylmalmide (NEM; #3876), BafilomycinA (#B1793) and cycloheximide (#C7698) is from
Sigma. MLN4924 (#B1036) is from ApexBio. Anti-HA monoclonal antibody (Covance #MMS101P, 1:1000 for WB), anti-HA polyclonal antibody (Abcam #9110, 1:1000 for WB), anti-Flag
monoclonal antibody (Sigma #F1804, 1:1000 for WB, 1:100 for IF), anti-Flag polyclonal
antibody (Sigma #F7425, 1:1000 for WB, 1:100 for IF), anti-SQSTM1 monoclonal antibody
(Novus #H00008878-M01, 1:1000 for WB, 1:100 for IF), anti-SQSTM1 polyclonal antibody
(Proteintech #18420-1-AP, 1:1000 for WB, 1:100 for IF), anti-Ub monoclonal antibody (FK2;
Biomol #PW-8810, 1:500 for WB, 1:100 for IF), anti-Ub polyclonal antibody (Dako #Z0458,
1:5000 for WB, 1:100 for IF), anti-Gapdh polyclonal antibody (Cell Signaling #2118, 1:1000 for
WB), anti-myc monoclonal antibody (Cell Signaling #2276, 1:1000 for WB), Anti-V5 HRP
antibody (Invitrogen #B96125, 1:1000 for WB), anti-LC3B polyclonal antibody (Sigma #L7543,
1:500 for WB), anti-Keap1 polyclonal antibody (SantaCruz #sc15246, 1:500).
Cell culture and transient transfection
Immortalized wild type and SQSTM1-/-MEFs were a kind gift by Dr. Komatsu, Niigata
University [11]. Keap1-/-MEFs were from Dr. Wakabayashi, University of Pittsburgh [78].
ATG5-/-MEFs were from Dr. Virgin, Washington University in St. Louis. MEFs were
maintained in in Dulbecco’s modified Eagle’s medium (DMEM, Gibco #11965-084), 10% fetal
bovine serum (FBS, Atlanta Biologicals #S10350H), and 50 μg/mL penicillin and streptomycin
(P/S, Sigma #P4333), 1% sodium pyruvate (Gibco #11360070), and 1% non-essential amino
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acid (Gibco #11140050) at 37°C with 5% CO2. U2OS cells were maintained in DMEM with
10% FBS, 50 μg/mL P/S at 37°C with 5% CO2. Transfection was performed with
lipofectamine2000 (Life Technologies #11668019) according to the manufacturer’s instruction.
24hr post-transfection, cells were washed three times with ice-chilled PBS and harvested in lysis
buffer. HA-human SQSTM1-WT gift from Dr. Moscat, Sanford-Burnham Medical Research
Institute [79], HA-SQSTM1 K420R, HA-SQSTM1 ΔUBA, ΔPB1, D69A P392L, M404V,
G411S, G425R generated using Quik Change Mutagenesis Kit (Agilent Technologies #200517).
HA-SQSTM1 6 K/R commercially synthesized by Genewiz and HA-SQSTM1 7 K/R generated
by mutagenesis. pDEST-mCherry-human SQSTM1 WT and pDEST-mCherry-eGFP-SQSTM1
WT gifted from Dr. Johansen, The Arctic University of Norway [18]. pDEST-mCherry-human
SQSTM1 P392L, M404V, G411S, G425R generated by mutagenesis. Flag-Ub-WT from Dr.
Yarden, Weizmann Institute of Science [80]. V5-Cul3, Cul3-Flag and Myc-Keap1 gifted from
Dr. Diehl, University of South Carolina [81]. DN-CUL3-FLAG from Addgene (#15820).
HttQ72-CFP previously described [82]. His-Ub purchased from Addgene (#31815).
Immunoprecipitation and Western blotting
Cells were harvested in NP-40 lysis buffers (50mM Tris pH7.7, 150mM NaCl, 1% NP-40) or
RIPA buffers (50mM Tris pH 7.7, 150mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulfate) with protease inhibitor cocktails (PIC; Sigma#P8340), 20mM NEM and
phenylmethylsulfonyl fluoride (PMSF; Sigma#P7626) and washed with ice-chilled PBS. Lysates
were centrifuged for 15mins at 4Cº, 16,000g. The supernatants were collected. Some lysates
were incubated with Usp2cc (1µg Usp2cc per 100µg cell lysates; R&D #O75604). 200μg of cell
lysates were pre-cleared for 1hr with end-over-end rotator with 10μg of dynabeads M-270 Epoxy
(Life Technologies #14302D) at 4°C. Samples were placed on a magnet and the supernatants
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were collected. The supernatants were incubated with antibody-conjugated Dynabeads on the
rotator at 4°C for 2hrs. For antibody conjugation, dialyzed antibodies were coupled to
Dynabeads M-270 Epoxy beads (Life Technologies #14311D) according to the manufacturer’s
instruction. After 2hr incubation, the samples were placed on the magnet and washed three times
with lysis buffer.
In the case of denaturing conditions, the assay was performed as previously described
[37]. Briefly, 10% of sample was kept as “input” samples. The rest of samples were mixed with
equal volume of 6M guanidine buffer (6M guanidine-HCl, 100mM sodium phosphate, 600mM
NaCl, 30mM imidazole, 0.05% Tween-20, pH 8.0). The mixed samples were pre-cleared for 1hr
on end-over-end rotator with 10μg of Dynabeads M-270 Epoxy at 4Cº. The samples were placed
on a magnetic stand and the supernatants were collected. The supernatants were incubated with
HisPur Ni-NTA Magnetic Beads (Thermo Sci#88831) on the rotator for 2hrs at 4Cº. The samples
were placed on a magnetic stand and washed twice with 8M urea buffer (8M urea, 100mM
sodium phosphate, 10mM Tris-Base, 50mM imidazole, pH 8.0). After all urea buffer completely
removed, the samples containing beads were incubated with elution buffer (250mM imidazole,
100mM sodium phosphate, 600mM NaCl) for 30mins on a rotator. The samples were mixed with
β-mercaptoethanol containing sample buffer and boiled at 95°C for 5mins. The Western blot
analysis was performed as previously described [83].
In vitro ubiquitination assay
Recombinant E2 enzyme (UbcH5a/UBE2D1; #E2-616) and ubiquitylation kit containing E1
enzyme (#K-995) were purchased from Boston Biochem. Recombinant fragment of Histidine
tagged human SQSTM1 (#SQSTM1-29505TH) containing amino acids 83-440 and was
purchased from Biomart. Cells were transfected with Cul3 WT-Flag or Cul3-D.N.-Flag. 24hrs
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after, cells were harvested in RIPA buffer and immunoprecipitated with Flag-antibodyconjugated Dynabead for 2hrs at 4°C. The samples were washed three times with lysis buffer and
incubated with E1, E2, ubiqutin and His-SQSTM1 (500ng) at 37°C for 1hr. The samples were
mixed with β-mercaptoethanol containing sample buffer and boiled at 95°C for 5mins.
Fractionation assay
SQSTM1-/-MEFs were grown in 10cm dishes at ~80% confluency. After three washes with icechilled PBS, cells were harvested in RIPA buffer with PIC, PMSF, and NEM. The cells were
sonicated for 10s, two times at 4°C. 10% of sample was taken from the lysate as a ‘total’
fraction. The remaining sample was centrifuged at 100,000g for 30mins at 4°C. After
centrifugation, the supernatant was transferred to a new tube and labeled as a ‘supernatant’
fraction. The rest of sample was resuspended in 200μl of 7M urea buffer (7M urea, 2M thiourea,
4% CHAPS, 30mM Tris, pH 8.5) and re-sonicated for 10s, two times at 4°C. The samples were
re-centrifuged at 100,000g for 30mins at 4°C. The supernatant was transferred to a new tube and
labeled as a ‘pellet’ fraction and the debris was discarded.
Cell viability assay
SQSTM1-/-MEFs grown at ~80% confluency were co-transfected with HttQ72-CFP and HASQSTM1. 24hr after the transfection, cells were washed three times with PBS. The assay was
performed according to the manufacturer’s instruction (Life Technologies #L-3224).
Immunocytochemistry and fluorescence microscopy
Cells were grown on glass coverslips prior to transfection with plasmid constructs. 24hrs after
the transfection, cells were washed three times with PBS, fixed in 4% PFA for 10mins and
permeabilized with 0.1% Triton X-100 in PBS for 10mins. After washing three times with PBS,
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cells were blocked with 2% BSA in PBS for 30mins-1hr at room temperature (RT). Cells were
stained with primary antibody at 4°C overnight followed by three-times washing with PBS. Cells
were incubated with Alexa 555 or 488 Fluor-conjugated secondary antibody at RT for 1hr and
mounted with Mowiol media containing DAPI. 10 random fields were taken with 20x objective
equipped in a NIKON Eclipse 80i fluorescence microscopy. Co-transfected cells were counted as
a total number of cells, and the cells containing ubiquitin-positive aggregates were counted using
ImageJ software (NIH). The images were presented in pseudo-color. For Cherry-eGFP-SQSTM1
assay, SQSTM1-/-MEFs were transfected with Cherry-eGFP-SQSTM1-WT, K420R, or T350A
along with or without Myc-Keap1/V5-Cul3 for 24hrs. Cells were washed two times with PBS
and mounted with Mowiol media containing DAPI without fixation to avoid pH disruption [57].
Pearson’s coefficient between red and green channel was measured by ImageJ.
Fluorescence recovery after photobleaching
SQSTM1-/-MEFs were grown on 1.5 Glass bottom 35mm dishes (MatTek #P35G-1.5-10-C) and
transfected with pDest-mCherry-SQSTM1 for 24hrs prior to imaging. Immediately before
imaging, the medium was replaced with Phenol Red-free medium (Gibco #21063029) containing
10% FBS, 50 μg/mL P/S, 1% sodium pyruvate, and 1% non-essential amino acid. The live cell
samples were placed on a heated chamber at 37°C with 5% CO2. The imaging and
photobleaching were performed with 40x oil objective using an NIKON A1Rsi confocal
microscopy. Before bleaching, the images of pre-bleached SQSTM1 bodies were taken. 561nm
laser was used to photobleach SQSTM1 bodies for 500ms. Immediately after the bleaching, the
images were collected every 2s for a total of 5mins as a post-bleached sample. The fluorescence
intensities of post-bleached SQSTM1 bodies were individually measured. In the meantime, the
fluorescence intensities of non-bleached SQSTM1 bodies were measured as a control. An
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average of SQSTM1 bodies in different cells (n≥7 cells containing SQSTM1 bodies) was
calculated. The relative florescence intensities were calculated as the average fluorescence
intensities of photobleached SQSTM1 bodies divided by the average fluorescence intensities of
pre-bleached samples.
Cycloheximide assay
Keap1-/- or control MEFs was transfected at ~80% confluency with empty vector or MycKeap1/V5-Cul3. 24hrs after the transfection, cells were treated with 10μg/mL cycloheximide for
varying time.
Statistical analysis
A two-tailed Student’s t-test was performed. For all tests, p-values<0.05 were considered
statistically significant. Data are represented as mean ± SEM.

26

2.4 Result
2.4.1 SQSTM1’s UBA domain is ubiquitinated at K420.
SQSTM1 associates with ubiquitinated proteins in cells [16]. We co-expressed HA-SQSTM1
and Flag-ubiquitin (Flag-Ub) in SQSTM1-/-mouse embryonic fibroblasts (MEFs) for 24 hours
and then immunoprecipitated with an HA antibody. Both SQSTM1 and Flag-Ub were detected
within the immunoprecipitate (Figure 1A). Interestingly, whereas Flag-Ub migrated as a high
molecular weight (HMW) species in the cell lysate, it migrated at ~75kDa in the HA
immunoprecipitant (Figure 1A). Moreover, an immunoblot of SQSTM1 from similar lysates
demonstrated both a 65kDa band and several HMW species (Figure 1A). This data suggested
that Flag-Ub was conjugated to SQSTM1. Treatment of cell lysates with the catalytic domain of
ubiquitin specific protease 2 (Usp2cc) collapsed the HMW species above SQSTM1 and
abolished the presence of Flag-Ub within the HA immunoprecipitant (Figure 1A). Nethylmaleimide (NEM) increased the amount of ubiquitinated SQSTM1 and inhibited the effect
of Usp2cc (Figure 1A).
We co-expressed both Flag-Ub and a HA-SQSTM1 construct that lacks its UBA domain,
SQSTM1-ΔUBA, and immunoprecipitated with an antibody to HA in SQSTM1-/-MEFs.
SQSTM1-ΔUBA failed to co-immunoprecipitate any Flag-Ub even in the presence of NEM
(Figure 1B). A similar experiment was performed that co-expressed Flag-Ub and a HA-SQSTM1
construct that lacks its N-terminal PB1 domain, SQSTM1-ΔPB1. Similar to SQSTM1-ΔUBA,
SQSTM1-ΔPB1 failed to co-immunoprecipitate any Flag-Ub (Figure 1C). To see if this related
to a lack of a critical lysine residue such as K7 or K13 that have been previously reported to be
ubiquitinated or related to a lack of SQSTM1 dimerization that is mediated via the PB1 domain,
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we performed the same experiment with HA-SQSTM1-D69A that fails to dimerize but maintains
all N-terminal lysines (Figure 1D) [36, 37]. Again, similar to SQSTM1-ΔPB1 no Flag-Ub was
immunoprecipitated suggesting that the dimerization of SQSTM1 may be critical for the
ubiquitination of SQSTM1’s C-terminal region.
To identify the principal lysine that is ubiquitinated on SQSTM1, we selected seven sites
as determined by mass spectrometry analysis and previous proteomic studies [36, 77, 84, 85].
We generated multiple HA-SQSTM1 mutant constructs with a lysine to arginine substitution
(K/R; Figure S1A). Notably, the HA tag does not contain a lysine. HA-SQSTM1 constructs were
co-transfected with Flag-Ub into SQSTM1-/-MEFs for 24 hours and then immunoprecipitated
with HA antibody in the presence of NEM. Mutation of all selected lysines, HA-SQSTM1-7K/R,
abolished the ubiquitination of SQSTM1 as seen by the absence of Flag-Ub in the
immunoprecipitant (Figure 1E). However, immunoprecipitation of SQSTM1 with mutations of 6
lysine residues (HA-SQSTM1-6K/R) that retains the C-terminal K420 residue demonstrates
Flag-Ub in a pattern similar to SQSTM1-WT (Figure1E). Changing the lysine at amino acid 420
to an arginine (HA-SQSTM1-K420R) diminished the amount of Flag-Ub in the
immunoprecipitant similar to HA-SQSTM1-ΔUBA expression suggesting that the principal
ubiquitinated lysine resides at K420 (Figure 1E).
To confirm that ubiquitin was indeed covalently attached to SQSTM1, we co-transfected
HA-SQSTM1-WT, HA-SQSTM1-K420R or SQSTM1-ΔUBA with histidine tagged ubiquitin
(His-Ub) into SQSTM1-/-MEFs for 24 hours and performed purification using a nickel charged
affinity resin in the presence of 6M guanidine. Consistent with our results in RIPA buffer, only
HMW HA-SQSTM1-WT was present in the affinity-purified lysate (Figure 1F).
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Input
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Figure1. SQSTM1 is ubiquitinated within its UBA domain. (A) anti-SQSTM1 and anti-Flag immunoblots of
HA-immunoprecipitated lysates from SQSTM1-/-MEFs expressing HA-SQSTM1 and Flag-Ub. Some lysates were
incubated with Usp2cc or NEM. (B) anti-SQSTM1 and anti-Flag immunoblots of HA-immunoprecipitated lysates
from SQSTM1-/-MEFs expressing HA-SQSTM1-WT or HA-SQSTM1-ΔUBA and Flag-Ub. Some lysates were
treated with NEM. (C) anti-HA and anti-Flag immunoblots of HA-immunoprecipitated lysates from SQSTM1-/MEFs expressing HA-SQSTM1-WT, HA-SQSTM1-ΔPB1, or HA-SQSTM1-ΔUBA and Flag-Ub. (D) anti-HA and
anti-Flag immunoblots of HA-immunoprecipitated lysates from SQSTM1-/-MEFs expressing HA-SQSTM1-WT or
HA-SQSTM1-D69A along with Flag-Ub. (E) anti-HA and anti-Flag immunoblots of HA-immunoprecipitated
lysates from SQSTM1-/-MEFs expressing HA tagged SQSTM1-WT, K/R, 6K/R, K420R or ΔUBA and Flag-Ub.
Anti-GAPDH serves as loading control for blots. (F) anti-HA immunoblots from SQSTM1-/-MEFs expressing HA,
HA-SQSTM1-WT, HA-SQSTM1-K420R, or HA-SQSTM1-ΔUBA and histidine tagged ubiquitin (His-Ub). AntiGAPDH serves as a loading control.
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2.4.2 The Cul3 complex ubiquitinates SQSTM1.
Since SQSTM1 interacts with Keap1, an adaptor for the E3 ligase Cul3, we expressed HASQSTM1-WT, HA-SQSTM1-K420R and HA-SQSTM1-ΔUBA with Flag-Ub and Myc-Cul3 in
SQSTM1-/-MEFs (Figure 2A) [40]. After 24 hours, immunoblotting for SQSTM1 demonstrated
an increase in ubiquitinated SQSTM1 in Myc-Cul3 expressing cells as evidenced by an increase
in HMW SQSTM1 bands that were not present in HA-SQSTM1-K420R or HA-SQSTM1ΔUBA expressing lysates (Figure 2A).
To further demonstrate that SQSTM1 could be ubiquitinated by Cul3 we transfected
SQSTM1-/-MEFs with an expression construct containing a Flag tagged Cul3-WT or an inactive
Cul3 that lacks its C-terminus (Cul3-DN) and immunoprecipitated Cul3 with an anti-Flag
antibody. Purified His-SQSTM1 lacking the first 84 amino acids of SQSTM1 and thus does not
contain two previously reported ubiquitination sites on SQSTM1 adjacent to the PB1 domain
(K7 or K13) was incubated with ubiquitin, immunoprecipitated Flag-Cul3 and recombinant
E1/E2 enzymes. Consistent with His-SQSTM1 ubiquitination there was an increase in its
molecular weight when Flag-Cul3-WT and not Flag-Cul3-DN was included in the reaction
(Figure 2B).
To function in ubiquitination reactions, Cul3 must be activated by, and bound to,
NEDD8, in a process called neddylation [86]. Cul3 activity can be inhibited using a nonspecific
neddylation inhibitor, MLN4924 [87]. Treatment of SQSTM1-/-MEFs expressing HA-SQSTM1
and Flag-Ub with MLN4924 and subsequent immunoprecipitation of HA-SQSTM1 abolished
SQSTM1 ubiquitination as assessed by Flag immunoblot (Figure 2C).
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Figure 2. The Cul3 complex ubiquitinates SQSTM1. (A) anti-SQSTM1 and anti-myc immunoblots of lysates
from SQSTM1-/-MEFs expressing HA tagged SQSTM1-WT, K420R or ΔUBA, Flag-Ub and myc-Cul3. A
representative blot is from three independent experiments. (B) Anti-Flag and anti-SQSTM1 immunoblot of
recombinant SQSTM1 (ΔN84) following in vitro ubiquitination with immunoprecipitated Flag-Cul3-WT or Cul3DN from SQSTM1-/-MEFs. (C) anti-HA and anti-Flag immunoblots of HA-immunoprecipitated lysates from
SQSTM1-/-MEFs expressing HA tagged SQSTM1-WT and Flag-Ub. Some cells were treated for 24hrs with 3µM
MLN4924. Anti-GAPDH serves as loading control for blots. A representative blot is from three independent
experiments.
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2.4.3 Keap1 modulates SQSTM1 ubiquitination.
Since SQSTM1 associates with Keap1, an adaptor of the Cul3 ligase complex, we reasoned that
SQSTM1 ubiquitination may be diminished in the absence of Keap1. We expressed HASQSTM1 and Flag-Ub in Keap1-/-MEFs with or without Myc-Keap1 for 24 hours and
immunoprecipitated the lysates with an HA antibody. The amount of ubiquitinated SQSTM1 was
increased when Myc-Keap1 was expressed in Keap1-/-MEFs (Figure 3A).
Immunoprecipitation of HA-SQSTM1 in SQSTM1-/-MEFs expressing Flag-Ub, V5-Cul3
and Myc-Keap1 demonstrated more ubiquitinated SQSTM1 as compared with expression of HASQSTM1 and Flag-Ub alone (Figure 3B). This ubiquitination was abrogated when Myc-Keap1ΔBTB that lacks its BTB domain, which is necessary for Cul3 association was expressed along
with V5-Cul3 further suggesting that the Keap1/Cul3 complex mediates ubiquitination of
SQSTM1 (Figure 3B).
SQSTM1 binds to Keap1 via its Keap1 interacting region (KIR). A single point mutation
in SQSTM1, T350A, abolishes this interaction [40]. To further establish that SQSTM1
ubiquitination is facilitated via Keap1, we expressed HA-SQSTM1-WT, HA-SQSTM1-T350A
or HA-SQSTM1-ΔUBA along with Flag-Ub in Keap1-/-MEFs with or without Myc-Keap1 for
24 hours and immunoprecipitated the lysates with an HA antibody. Whereas Myc-Keap1 coexpression increased ubiquitinated HA-SQSTM1-WT as detected by Flag antibody, there was no
augmentation of HA-SQSTM1-T350A when Myc-Keap1 was also expressed (Figure 3C).
Since the previous studies used an overexpressed human SQSTM1 construct in knockout
mouse cells (see Figure S1B for level of overexpression as compared to control lines), we
wanted to establish that endogenous SQSTM1 was indeed ubiquitinated. To do this, we
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expressed His-Ub in U20S cells treated with vehicle or MLN4924 for 24 hours and performed
purification using a nickel charged affinity resin in the presence of 6M guanidine.
Immunoblotting of the purified lysate with an antibody to SQSTM1 demonstrated a HMW smear
in His-Ub transfected cells that was reduced when MLN4924 was added to the cells (Figure 3D).
Similarly, we expressed Myc-Keap1 and V5-Cul3 in U20S cells or treated these cells with
MLN4924. Lysates were then immunoblotted with a polyclonal antibody to SQSTM1. MycKeap1/V5-Cul3 co-expression increased the amount of a second band migrating above SQSTM1
and this band disappeared with MLN4924 treatment (Figure 3E).
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Figure 3. Keap1 modulates SQSTM1 ubiquitination. (A) Anti-HA and anti-Flag immunoblots of HAimmunoprecipitated lysates from Keap1-/-MEFs expressing HA-SQSTM1-WT, Flag-Ub and myc-Keap1. (B) AntiHA and anti-Flag immunoblots of HA-immunoprecipitated lysates from SQSTM1-/-MEFs expressing HASQSTM1, Flag-Ub, V5-cul3 and myc-Keap1-WT or myc-Keap1-ΔBTB. (C) Anti-HA, anti-Flag, and LC3
immunoblots of HA-immunoprecipitated lysates from Keap1-/-MEFs expressing Flag-Ub, HA-SQSTM1-WT, HASQSTM1-T350A or HA-SQSTM1-ΔUBA with or without myc-Keap1. (D) anti-SQSTM1 immunoblot of nickel
resin purified lysates from U20S cells expressing His-Ub and treated with DMSO or MLN4924. (E) Anti-SQSTM1
immunoblot of lysates from U20S cells with or without Myc-Keap1/V5-Cul3 expression or treated with MLN4924.
Anti-GAPDH serves as loading control for blots.
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2.4.4 Keap1/Cul3-mediated ubiquitination of SQSTM1 increases sequestering
activity.
SQSTM1’s sequestering activity is required for ubiquitinated inclusion body formation in the
setting of autophagic impairment and loss of SQSTM1 leads to a reduction of insoluble
ubiquitinated proteins with a concomitant accumulation of soluble ubiquitinated proteins [11].
To explore this function, we expressed control vector, HA-SQSTM1-WT, HA-SQSTM1-K420R
and HA-SQSTM1-ΔUBA in SQSTM1-/-MEFs and fractionated cell lysates via
ultracentrifugation (Figure 4A). In the absence of SQSTM1, ubiquitinated proteins remain in the
supernatant and do not shift to the pelleted fraction. HA-SQSTM1-WT was enriched in the
pelleted fraction along with HMW ubiquitinated proteins. In contrast, HA-SQSTM1-K420R and
HA-SQSTM1-ΔUBA were enriched in the supernatant fraction and did not shift ubiquitinated
proteins to the pelleted fraction.
Expression of HA-SQSTM1-WT in SQSTM1-/-MEFs generated multiple punctate
ubiquitin positive inclusions throughout the cytoplasm. In contrast, HA-SQSTM1-ΔUBA and
HA-SQSTM1-K420R had markedly fewer ubiquitin positive inclusions (Figure 4B-C). The coexpression of Myc-Keap1, V5-Cul3 or Myc-Keap1/V5-Cul3 increased the percentage of HASQSTM1-WT expressing cells containing ubiquitinated aggregates that did not occur in cells
expressing HA-SQSTM1-K420R (Figure 4B and Figure S2). Similarly, we expressed mCherrySQSTM1-WT and mCherry-SQSTM1-K420R in SQSTM1-/-MEFs or ATG5-/-MEFs and
quantitated the average size of SQSTM1 bodies. mCherry-SQSTM1-WT formed larger
SQSTM1 bodies and this was greater in ATG5-/-MEFs (Figure 4D-E). Co-expression of MycKeap1/V5-Cul3 further increased mCherry-SQSTM1-WT body size in both cell types but
mCherry-SQSTM1-WT body size did not increase when Myc-Keap1-ΔBTB/V5-Cul3 was coexpressed. In control fibroblasts, co-expression of Myc-Keap1/V5-Cul3 increased mCherry38

SQSTM1-WT body size but this augmentation did not occur with mCherry-SQSTM1-T350A
expression (Figure 4F). Co-expression of Myc-Keap1/V5-Cul3 increased the size of endogenous
SQSTM1 bodies, and MLN4924 treatment significantly decreased the size in U20S cells (Figure
S3).
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Figure 4. Keap1/Cul3-mediated ubiquitination of SQSTM1 increases sequestering activity. (A) Anti-HA and
anti-ubiquitin immunoblots of cellular lysates (10% of total, supernatant and pellet) from SQSTM1-/-MEFs
expressing empty HA vector, HA-SQSTM1-WT, HA-SQSTM1-K420R, or HA-SQSTM1-ΔUBA. (B) Quantitation
of SQSTM1-/-MEFs expressing HA-SQSTM1-WT, HA-SQSTM1-K420R, HA-SQSTM1-ΔUBA or co-transfected
with myc-Keap1 and myc-Keap1/V5-cul3 containing ubiquitinated inclusions. Representative data is pooled from
four independent experiments. All data are represented as mean ± SEM. *p<0.05. (C) Anti-Ub immunostaining of
SQSTM1-/-MEFs expressing empty vector, HA-SQSTM1-WT, K420R or ΔUBA. The scale bar indicates 1 µm. (D)
Quantitation of SQSTM1 body size in SQSTM1-/- and ATG5-/- MEFs expressing mCherry tagged SQSTM1-WT or
-K420R with myc-Keap1, myc-Keap1- ΔBTB and V5-Cul3. All data are represented as mean ± SEM. *p<0.05. (E)
Representative images of ATG5-/-MEFs expressing Cherry-SQSTM1-WT or K420R along with Myc-Keap1/V5Cul3. The scale bar indicates 1 µm. (F) Quantitation of SQSTM1 body size in MEFs expressing mCherry tagged
SQSTM1-WT or T350A with or without myc-Keap1/V5-cul3. All data are represented as mean ± SEM. *p<0.05.
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Figure S2. SQSTM1 expression level. (A) Anti-SQSTM1immunoblot of SQSTM1-/-MEFs expressing empty
vector, HA-SQSTM1-WT, K420R or ΔUBA. Anti- GAPDH was used as a loading control. (B) Anti-SQSTM1, antiMyc and anti-V5-HRP immunoblots of SQSTM1-/-MEFs expressing HA-SQSTM1-WT or K420R along with MycKeap1/V5-Cul3. Anti-GAPDH was used as a loading control.

Figure S2. SQSTM1 expression level (Related to Fig 4)
(A) Anti-SQSTM1immunoblot of SQSTM1-/-MEFs expressing empty vector, HA-SQSTM1-WT, K420R or ΔUBA. AntiGAPDH was used as a loading control. (B) Anti-SQSTM1, anti-Myc and anti-V5-HRP immunoblots of SQSTM1-/-MEFs
expressing HA-SQSTM1-WT or K420R along with Myc-Keap1/V5-Cul3. Anti-GAPDH was used as a loading control.
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Figure S3. Endogenous SQSTM1 body size. Quantitation of endogenous SQSTM1 body size in U2OS cells
expressing myc-Keap1/V5-cul3 or treated with 3 μM MLN4924 for 24hrs. All data are represented as mean ± SEM.
*p<0.05. (n≥100)
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2.4.5 SQSTM1 ubiquitination modulates its exchange rate
mCherry-SQSTM1-WT or SQSTM1-K420R was expressed in SQSTM1-/-MEFs and live cell
imaging was performed to evaluate fluorescence recovery after photobleaching (FRAP) of
individual puncta. The initial rapid phase of recovery has been suggested to correlate with
SQSTM1’s sequestering activity [32]. The fluorescence exchange rate of mCherry-SQSTM1K420R was more rapid than mCherry-SQSTM1-WT and co-expression of Myc-Keap1/V5-Cul3
decreased fluorescence recovery whereas co-expression of Myc-Keap1-ΔBTB/V5-Cul3
increased fluorescence recovery (Figure 5A-B). In a similar experiment, the co-expression of
Myc-Keap1/V5-Cul3 failed to decrease the fluorescence recovery of mCherry-SQSTM1-T350A
(Figure 5C). The differences in fluorescent recovery were not due to SQSTM1 presence within
an autophagosome since an experiment performed in ATG5-/-MEFs gave similar results (Figure
S4A-B).
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Figure 5. SQSTM1 ubiquitination modulates its exchange rate. (A) The average RFI following photobleaching
from SQSTM1-/-MEFs expressing mCherry-SQSTM1-WT or K420R and V5-Cul3 with myc-Keap1-WT or mycKeap1-ΔBTB. Representative data is pooled from four independent experiments. (B) Representative live cell images
of mCherry-SQSTM1-WT or K420R and V5-cul3 with myc-Keap1-WT or myc-Keap1-ΔBTB following
photobleaching and fluorescent recovery. The circle indicates the photobleached area. The scale bars indicate 1 µm.
(C) The average RFI following photobleaching from SQSTM1-/-MEFs expressing mCherry-SQSTM1-WT or
T350A and V5-Cul3 with myc-Keap1-WT. Representative data is pooled from three independent experiments.
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Figure S4
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SEM.

2.4.6 Keap1/Cul3-mediated ubiquitination of SQSTM1 facilitates its role in
autophagy
We reasoned that the increased SQSTM1 exchange rate seen with mCherry-SQSTM1-K420R as
compared with mCherry-SQSTM1-WT may reduce phagophore association with SQSTM1. To
test this, we expressed HA-SQSTM1-WT or HA-SQSTM1-K420R with Flag-Ub in SQSTM1-/MEFs for 24 hours. Cell lysates were immunoprecipitated with an anti-HA antibody and
immunoblotted for HA and LC3B. HA-SQSTM1-K420R immunoprecipitants had less LC3BII
as compared with HA-SQSTM1-WT (Figure 6A). Consistent with this, cell lysates
immunoprecipitated with anti-HA from SQSTM1-/-MEFs expressing HA-SQSTM1-WT with
Flag-Ub, Myc-Keap1 and V5-Cul3 in SQSTM1-/-MEFs had an increase in LC3BII association
as observed on immunoblots probed with HA and LC3 (Figure 6B). Similarly, whereas MycKeap1/V5-Cul3 co-expression increased HA-SQSTM1-WT association with LC3B, this was not
seen for HA-SQSTM1-T350A (Figure 3C).
To further explore the role of UBA domain ubiquitination by Keap1/Cul3 on SQSTM1’s
degradation, we expressed tandem tagged mCherry-GFP-SQSTM1-WT in SQSTM1-/-MEFs for
24hours with and without BafilomycinA (BafA) (Figure 6C). When mCherry-GFP-SQSTM1WT is in the cytosol as an inclusion body or within the non-acidic environment of an
autophagosome, both mCherry and GFP fluorescence is present [18]. However, when mCherryGFP-SQSTM1-WT enters an acidic environment such as an autolysosome, GFP fluorescence
quenches leaving only mCherry fluorescence. Consistent with this, the degree of mCherry:GFP
co-localization was increased in BafA-treated cells as compared with untreated cells (Figure 6C
and Figure S5A-B). In addition, co-expression of Myc-Keap1/V5-Cul3 with mCherry-GFPSQSTM1-WT decreased the degree of mCherry:GFP co-localization suggesting that SQSTM1
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ubiquitination enhances its autophagic degradation (Figure 2.4.6C). This effect was not seen in
the presence of BafA.
The ratio of mCherry:GFP co-localization in SQSTM1-/-MEFs expressing mCherryGFP-SQSTM1-K420R or mCherry-GFP-SQSTM1-T350A was significantly increased as
compared to mCherry-GFP-SQSTM1-WT suggesting that fewer SQSTM1-K420R or SQSTM1T350A puncta were within autolysosomes (Figure 6C). In contrast to mCherry-GFP-SQSTM1WT puncta, there was not a decrease in mCherry:GFP co-localization with Myc-Keap1/V5-Cul3
expression in mCherry-GFP-SQSTM1-K420R or mCherry-GFP-SQSTM1-T350A expressing
SQSTM1-/-MEFs (Figure 6C).
We reasoned that the increase in mCherry:GFP co-localization in SQSTM1-/-MEFs
expressing mCherry-GFP-SQSTM1-K420R or mCherry-GFP-SQSTM1-T350A was due to its
cytoplasmic accumulation in inclusion bodies rather than accumulation within autophagosomes.
Consistent with this, SQSTM1-/-MEFs expressing mCherry-SQSTM1-K420R or mCherrySQSTM1-T350A had a reduction in co-localization with co-expressed GFP-LC3B as compared
to mCherry-SQSTM1-WT expressing SQSTM1-/-MEFs (Figure 6D). Moreover, expression of
Myc-Keap1/V5-Cul3 increased the GFP-LC3B or endogenous LC3B co-localization with
mCherry-SQSTM1-WT but failed to do so in mCherry-SQSTM1-K420R or mCherry-SQSTM1T350A expressing SQSTM1-/-MEFs (Figure 6D and Figure S5C).
Further studies demonstrated that the stability of endogenous SQSTM1 was increased in
Keap1-/-MEFs as compared with control MEFs when cell lysates were immunoblotted for
SQSTM1 from cells treated with cycloheximide for varying times (Figure 6E). This increase in
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SQSTM1 stability was abrogated in Keap1-/-MEFs that were transfected with Myc-Keap1/V5Cul3 expression constructs.
The expression of HttQ72-CFP in SQSTM1-/-MEFs is toxic with only ~5% of
transfected cells remaining viable 24 hours post transfection (Figure 6F). This toxicity is rescued
when HA-SQSTM1-WT is expressed but not by HA-SQSTM1-K420R, HA-SQSTM1-ΔUBA or
HA-SQSTM1-T350A (Figure 6F). The expression of Myc-Keap1 and/or V5-Cul3 without HASQSTM1-WT in SQSTM1-/-MEFs did not significantly change HttQ72-CFP toxicity. However,
the co-expression of Myc-Keap1/V5-Cul3 along with HA-SQSTM1-WT enhanced cell viability.
This effect was not seen in the setting of HA-SQSTM1-K420R, HA-SQSTM1-ΔUBA or HASQSTM1-T350A (Figure 6F).
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Figure 6. Keap1/Cul3-mediated ubiquitination of SQSTM1 facilitates its role in autophagy. (A) Anti-HA and
anti-LC3 immunoblots of HA-immunoprecipitated lysates from SQSTM1-/-MEFs expressing HA-SQSTM1-WT or
K420R and Flag-Ub. (B) Anti-HA and anti-LC3 immunoblots of HA-immunoprecipitated lysates from SQSTM1-/MEFs expressing HA-SQSTM1-WT and Flag-Ub with and without Myc-Keap1 and V5-Cul3. (C) Graph of the
Pearson’s coefficient of co-localization of mCherry:GFP fluorescence in SQSTM1-/-MEFs expressing a dual
fluorescent reporter mCherry-GFP fused to SQSTM1-WT, K420R or T350A with or without myc-Keap1 and V5Cul3. Some cells were also with BafA. Representative data is pooled from three independent experiments. (D)
Quantitation of the percent of mCherry-SQSTM1 bodies that co-localize with GFP-LC3 in SQSTM1-/-MEFs
expressing mCherry fused SQSTM1-WT, K420R or T350A with or without Myc-Keap1 and V5-Cul3.
Representative data is pooled from three independent experiments. (E) Anti-SQSTM1 immunoblot of lysates from
control or Keap1-/-MEFs treated with cycloheximide for the indicated times. Some cells were also transfected with
Myc-Keap1 and V5-Cul3. The percent of remaining SQSTM1 was quantified from three independent experiments
and is represented graphically. (F) Quantitation of the percent of HttQ72-CFP positive SQSTM1-/-MEFs expressing
HA-SQSTM1-WT, K420R, ΔUBA, T350A or co-expressing myc-Keap1 and V5-cul3. All data are represented as
mean ± SEM. *p<0.05. Anti-GAPDH serves as loading control for blots. Representative data is pooled from three
independent experiments.
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2.4.7 UBA domain ubiquitination in SQSTM1 is diminished with disease
mutations.
Some SQSTM1 disease mutations reside within its UBA domain (Figure S1A) [55]. We
expressed HA-SQSTM1-WT, SQSTM1-K420R and 5 different disease mutations, SQSTM1A390X (equivalent to SQSTM1-ΔUBA used above), SQSTM1-P392L, SQSTM1-M404V,
SQSTM1-G411S, and SQSTM1-G425R along with Flag-Ub in SQSTM1-/-MEFs (Figure 7A).
Following 24 hours, we immunoprecipitated cell lysates with an HA antibody and
immunoblotted for Flag and HA. Immunoprecipitants from HA-SQSTM1-WT but not HASQSTM1-K420R or HA-SQSTM1-A390X had Flag immunoreactive bands (Figure 7A). In
addition, all expressed SQSTM1 disease mutants showed an absence or reduction in Flag
immunoreactivity (Figure 7A). FRAP analysis of mCherry-SQSTM1-WT, SQSTM1-P392L,
SQSTM1-M404V, SQSTM1-G411S or SQSTM1-G425R in SQSTM1-/-MEFs demonstrated
that fluorescence recovery was more rapid with all disease mutants as compared with mCherrySQSTM1-WT (Figure 7B). HA-SQSTM1-WT increased the number of live cells expressing
HttQ72-CFP and this was augmented with co-expression of Keap1/Cul3 in SQSTM1-/-MEFs
(Figure 7C). Whereas, expression of SQSTM1 disease mutants, with the exception of HASQSTM1-P392L, significantly decreased cell viability compared to HA-SQSTM1-WT. Coexpression of Keap1/Cul3 in SQSTM1 disease mutant-expressing cells reduced cell death.
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Figure 7. SQSTM1 disease mutants have decreased ubiquitination and function. (A) Anti-HA and anti-Flag
immunoblots of HA-immunoprecipitated lysates from SQSTM1-/-MEFs expressing HA-SQSTM1-WT, SQSTM1K420R, SQSTM1-ΔUBA, SQSTM1-P392L, SQSTM1-M404V, SQSTM1-G411S, SQSTM1-G425R and Flag-UbWT. Anti-GAPDH is used as loading control. (B) The average RFI following photobleaching from SQSTM1-/MEFs expressing mCherry-SQSTM1-WT, SQSTM1-P392L, SQSTM1-M404V, SQSTM1-G411S or SQSTM1G425R. (C) Quantitation of the percent of HttQ72-CFP positive SQSTM1-/-MEFs expressing HA-SQSTM1-WT,
P392L, M404V, G411S, G425R or co-expressing myc-Keap1 and V5-Cul3. All data are represented as mean ±
SEM. *p<0.05. Representative data is pooled from three independent experiments.
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2.5 Discussion
The present study finds that SQSTM1 is ubiquitinated at a highly conserved lysine within its
UBA domain (K420) by Keap1/Cul3. Substitution of K420 to arginine, deletion of the UBA
domain or mutation of the KIR domain in SQSTM1 decreases ubiquitinated inclusion formation,
its LC3 interaction and cell viability. In contrast, Keap1/Cul3 expression can increase
ubiquitinated inclusion formation, SQSTM1 inclusion body size and rescue cells from
proteotoxic stress. Moreover, Keap1/Cul3 increases SQSTM1’s association with LC3B and its
subsequent degradation. We propose that the ubiquitination of SQSTM1’s UBA domain by
Keap1/Cul3 enhances its sequestration activity, subsequent phagophore association and
degradation.
The molecular assembly of SQSTM1 oligomers is necessary for its function in
autophagy. How this assembly is regulated is not fully understood. Recent studies support a
model where the self-association of SQSTM1 occurs via its PB1 domain [51]. This interaction is
a nidus for the extension of a filamentous SQSTM1 scaffold that allows the engulfing
phagophore membrane to bind the LIR domain and degrade ubiquitinated proteins [53]. Deletion
of the PB1 domain abrogates the self-association of SQSTM1 reducing SQSTM1’s sequestration
activity and cellular function [16]. Similarly, deletion of SQSTM1’s UBA domain impairs
SQSTM1 body formation even in the setting of an intact PB1 domain. SQSTM1’s UBA domain
can also self-associate as a dimer [46]. Phosphorylation of serines 403 and 409 within the UBA
domain destabilize this dimer and regulates SQSTM1’s activity [32, 47]. These studies suggest
that SQSTM1’s molecular assembly is dependent upon both its PB1 and UBA domains.
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The UBA domain of SQSTM1 has a shared interface that mediates dimerization and
ubiquitin binding. Ubiquitin binding and UBA domain dimerization are mutually exclusive with
dimerization “inactivating” ubiquitin binding [46]. Amino acid K420 resides at the C-terminus of
helix 2. Structural studies have demonstrated that this region of SQSTM1’s UBA domain
interacts with residues in loop 1. Indeed, point mutations in loop 1 residues (E409K, G410K) or
helix 2 (T419K) disrupt dimerization (Long et al., 2010). Whether ubiquitination of K420
disrupts dimerization allowing for increased ubiquitin binding is unclear. Alternatively, K420
ubiquitination may serve as means for increased oligomer formation via interaction of a
SQSTM1 UBA domain with an adjacent SQSTM1’s ubiquitinated UBA domain or interactions
with other proteins harboring ubiquitin-binding motifs.
More recently, it was demonstrated that polyubiquitin could fragment SQSTM1 filaments
suggesting that the oligomeric structure of SQSTM1 was dynamic and could change with the
addition of ubiquitinated cargo [51]. Our data extends this model and suggests that the
ubiquitination status of SQSTM1’s UBA domain may alter SQSTM1’s oligomeric structure thus
promoting inclusion body formation. This higher ordered SQSTM1 oligomer would then further
promote SQSTM1’s sequestration activity, subsequent phagophore assembly and autophagic
degradation. We suggest that by refining SQSTM1’s oligomeric structure via UBA domain
ubiquitination, autophagic degradation and sequestration activity can be activated or inhibited
locally within the SQSTM1 inclusion body.
The ubiquitination of autophagic adaptors is emerging as a means of regulating their
function. Ubiquitination of optineurin by HACE1 increases its association with SQSTM1
enhancing autophagic flux and suppressing tumor growth [33]. TRIM21 ubiquitinates SQSTM1
on its N-terminal PB1 domain inhibiting SQSTM1 oligomerization and sequestration activity
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[37]. This event would antagonize Keap1/Cul3 mediated ubiquitination at the C-terminal UBA
domain suggesting that the ubiquitination of SQSTM1 can both positively and negatively affect
its sequestration function. Recently, the E3 ligase RPN26 was found to recruit and ubiquitinate
SQSTM1’s UBA domain at the ER membrane [34]. This event enhanced SQSTM1’s ability to
capture a subset of endosomes via binding to ubiquitin binding domains on endocytic adaptors.
Whether RPN26 ubiquitinates K420 or another lysine within the UBA domain is not established.
Previous studies have found that a Keap1 homodimer binds to two sites on Nrf2
facilitating Cul3 mediated ubiquitination. Oxidative stress destabilizes Keap1 and abrogates it
interactions with Nrf2. Keap1 binds SQSTM1 at a single KIR domain. The affinity for this
interaction becomes greater as SQSTM1 accumulates under conditions of impaired autophagy,
sequestering Keap1 from Nrf2 leading to its stabilization [40, 42, 45]. Similarly, Keap1
accumulates under conditions of impaired autophagy or in the setting SQSTM1 knockdown [88].
Autophagic degradation of Keap1 through its interaction with SQSTM1 may help to maintain
redox homeostasis [89]. In fact, Keap1 itself enhances SQSTM1 mediated ubiquitin aggregate
clearance [90]. This may further serve to regulate Keap1 levels and its interactions with both
Nrf2 and SQSTM1.
Our data suggests that Keap1/Cul3 can ubiquitinate SQSTM1 and enhance its autophagic
activity. Only dimeric SQSTM1 is able to be ubiquitinated since SQSTM1 with a PB1 domain
deletion or SQSTM1-D69A fail to be ubiquitinated (Figure 1C and 1D). This would suggest that
a Keap1 homodimer binds to two high affinity KIR motifs on a SQSTM1 dimer leading to its
ubiquitination. This model is similar to alternative models of Keap1 which suggests that a
homodimer can associate with two Nrf2 molecules or with Nrf2 and a second protein with a KIR
motif, such as PGAM5 which then targets this complex to the mitochondria [91, 92].
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Interestingly, loss of Keap1 stabilizes SQSTM1 whereas increased expression of Keap1/Cul3
increases SQSTM1 inclusion formation and subsequent degradation. Whether Keap1 is further
degraded along with SQSTM1 is not known. However, Keap1/Cul3 mediated ubiquitination and
subsequent enhancement of SQSTM1 degradation would be an efficient means by which Keap1
could decrease the levels of SQSTM1 thus releasing its antagonistic interaction.
Dominantly inherited mutations in SQSTM1 are associated with several degenerative
diseases ranging from PDB to ALS [55]. More recently, homozygous loss of function mutations
in SQSTM1 were identified in patients with childhood onset neurodegeneration [93]. Some
SQSTM1 disease mutations reside within or lead to premature truncations of the UBA domain
[55]. One unifying feature for these mutations is variable degrees of impaired ubiquitin binding
in vitro [76]. Our data finds that UBA domain associated SQSTM1 disease mutations also have a
reduction in UBA domain ubiquitination. More recently, several SQSTM1 missense mutations
associated with PDB and ALS have been identified within the Keap1 interacting region [58, 94].
These mutations lead to a loss of Keap1 interaction and a reduction in Nrf2 signaling. It is
intriguing to speculate that these mutations may also affect Keap1/Cul3 associated ubiquitination
of SQSTM1’s UBA domain further unifying the pathogenic mechanism of SQSTM1 mutations.
Alternatively, xenophagy associated phosphorylation of SQSTM1 at serine 349 can be disrupted
by a point mutation within the UBA domain that diminishes its ubiquitin binding function [95].
The phosphorylation of serine 349 on SQSTM1 then increases SQSTM1’s affinity for Keap1
[41]. It is also conceivable that UBA domain associated disease mutations in SQSTM1 affect
serine 349 phosphorylation abrogating Keap1/Cul3 mediated ubiquitination of the UBA domain.
The modulation of SQSTM1 activity via Keap1/Cul3 offers an attractive therapeutic
target. Expression of Keap1/Cul3 increases SQSTM1’s sequestration activity. In the case of
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SQSTM1 associated disease mutations, Keap1/Cul3 expression restored SQSTM1’s
cytoprotective role in polyglutamine toxicity. Whether Keap1/Cul3 mediated ubiquitination of
SQSTM1 further enhances the sequestration of Keap1 resulting in the non-canonical activation
of Nrf2, which may further enhance cell viability remains to be established. Indeed, activation of
Nrf2 is cytoprotective in models of polyglutamine toxicity [96]. Our present data further
connects SQSTM1-mediated autophagy with the Keap1-Nrf2 signaling pathway.
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Chapter 3: TIA1 variant drives
myodegeneration in multisystem
proteinopathy with SQSTM1 mutations
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3.1 Abstract
Disturbances of stress granule (SG) dynamics and autophagic protein degradation underlie the
pathogenesis of a spectrum of degenerative diseases that affect muscle, brain and bone termed
multisystem proteinopathy (MSP). Specifically, identical mutations in the autophagic adaptor
SQSTM1 can cause varied penetrance of four distinct phenotypes; amyotrophic lateral sclerosis,
frontotemporal dementia, Paget’s disease of the bone and distal myopathy. It has been
hypothesized that clinical pleiotropy relates to additional genetic determinants, but thus far
evidence has been lacking. Here, we provide evidence that a TIA1 (p.N357S) variant dictates a
myodegenerative phenotype when inherited along with a pathogenic SQSTM1 mutation.
Experimentally, the TIA1-N357S variant significantly enhances liquid-liquid phase separation in
vitro and impairs SG dynamics in living cells. Depletion of SQSTM1 or introduction of a mutant
version of SQSTM1 similarly impairs SG dynamics. TIA1-N357S persistent SGs exhibit
increased association with SQSTM1, accumulation of ubiquitin conjugates and additional
aggregated proteins. Synergistic expression of the TIA1-p.N357S variant and a SQSTM1p.A390X mutation in myoblasts exhibit impaired SG clearance and myotoxicity relative to
control myoblasts. These findings demonstrate a pathogenic connection between SG homeostasis
and ubiquitin mediated autophagic degradation that defines the penetrance of a MSP phenotype.
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3.3 Introduction
Pathogenic mutations in some genes lead to a spectrum of variably penetrant phenotypes that
span different organs and postmitotic tissue [2, 62, 75, 97]. For example the same mutation in the
autophagic adaptor protein, SQSTM1 (also known as p62), can cause Paget’s disease of the bone
(PDB), rimmed vacuolar inclusion body myopathy (RV-IBM), amyotrophic lateral sclerosis
(ALS) or frontotemporal dementia (FTD) [75]. The term multisystem proteinopathy (MSP) has
become useful to describe this growing family of genetic diseases that so far have been reported
with dominant mutations in the pleotropic genes VCP, HNRNPA2B1, HNRNPA1 and SQSTM1
[2, 62, 75, 97]. Other disease associated genes with variably penetrant phenotypic expression of
RV-IBM, ALS and FTD, yet no association with PDB, include TIA1 and MATR3 [60, 61, 98].
One distinctive feature of MSP pedigrees is that patients with the same mutation and even the
same mutation within a family can manifest with different phenotypes (i.e. PDB in one sibling
and ALS in another sibling). MSP also unifies two key pathologic features in affected tissue,
ubiquitinated aggregates and the accumulation of RNA binding proteins with low complexity
sequence domains (LCD) such as TDP-43 [2].
Mutations in several proteins that facilitate ubiquitin-dependent autophagy such as VCP,
SQSTM1, UBQLN2, and OPTN are associated with PDB, RV-IBM, ALS and FTD [75, 97, 99,
100]. Disease mutations in these proteins impair the degradation and clearance of ubiquitinated
inclusions resulting in their accumulation. SQSTM1 is an autophagic adaptor protein with a
UBA domain and autophagosome interacting motif [101]. Most pathogenic variants in SQSTM1
are missense mutations within or truncations of the UBA domain [55]. These mutations affect
SQSTM1’s oligomerization and ability to recruit ubiquitinated aggregates to the autophagosome
64

suggesting that the pathogenesis of MSP and its related diseases are due in part to alterations in
protein homeostasis and particularly autophagic degradation of ubiquitinated proteins in
vulnerable tissues [55]. One disease associated SQSTM1 mutation that has been demonstrated to
cause the full spectrum of MSP phenotypes (PDB, RV-IBM, ALS and FTD) is a proline to a
leucine mutation at residue 392 (P392L) in the UBA domain [3-6]. This single mutation is the
most common genetic cause of PDB but is incompletely penetrant suggesting that other genetic
or environmental factors are needed for the phenotypic manifestation of PDB, RV-IBM, ALS or
FTD [102].
One distinctive pathologic feature seen in MSP affected tissues is accumulation of
cytoplasmic inclusions of RNA-binding proteins such as TDP-43 [2]. Indeed, mutations in RNAbinding proteins with LCDs, including TARDBP, FUS, HNRNPA2B1, HNRNPA1, TIA1 and
HNRPDL cause dominantly inherited forms of MSP, ALS, FTD and RV-IBM [60-65]. These
RNA-binding proteins promote the assembly of membrane-less organelles such as stress
granules through the biophysical process of liquid-liquid phase separation (LLPS) that is
mediated via the LCD [67]. Importantly, disease-causing mutations in the LCD of these RNAbinding proteins alters their biophysical properties, increase their propensity to undergo LLPS
and result in the accumulation of poorly dynamic stress granules that are believed to underlie
cellular dysfunction and evolve into the pathological inclusions characteristic of these diseases
[60, 67, 103]. Notably, TIA1 is a key component of cytosolic stress granules [60]. Dominantly
inherited mutations within TIA1’s LCD cause MSP or more discreet clinical manifestations of
either ALS-FTD or a distinctive form of distal myopathy termed Welander distal myopathy
(WDM) [60, 61]. As with hnRNPA1, hnRNPA2B1, and TDP-43, disease mutations in the LCD
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of TIA1 alter its biophysical properties, promote LLPS, enhance fibrillization and impair stress
granule clearance as a mechanism of their pathogenicity [60, 61].
RV-IBMs are defined by a core set of pathologic features; rimmed vacuoles (RVs) and
inclusion bodies, seen in degenerative myopathies [104]. RVs are present within some myofibers
and contain autophagic and membranous debris, such as SQSTM1 and MAP1LC3. Many
proteins have been identified to accumulate as inclusions in RV-IBM tissue. These proteins
include ubiquitin, β-amyloid and TDP-43; with TDP-43 aggregation being specific for RV-IBMs
[104]. In many cases, protein inclusions and vacuolar debris are stained by Congo red and
demonstrate birefringence suggesting they are true amyloid. Accumulating studies now establish
that the presence of SQSTM1 and/or TDP-43 within myofibers serve as markers of muscle
degeneration in RV-IBMs [105-108].
The relationship between stress granule homeostasis and autophagic protein degradation
has been demonstrated in cell culture [73, 109]. Specifically, autophagy participates in stress
granule clearance. Autophagy mediated stress granule clearance may also require the ubiquitinsegregase VCP [73, 109]. Autosomal dominantly inherited mutations in VCP cause MSP but
whether its pathogenesis is mediated via its effect on stress granule homeostasis is not known
[97]. The present study identifies a rare variant in TIA1 that dictates the tissue specificity
associated with SQSTM1 mutations. Digenic inheritance of a TIA1-N357S variant with a
pathogenic SQSTM1 mutation causes a distal myopathy with RV-IBM pathology. This finding
connects stress granule homeostasis with ubiquitin dependent autophagic degradation as a key
mediator of phenotypic outcome within the spectrum of RV-IBM, ALS and FTD, and shows the
relevance of oligogenic mechanisms as one cause of neurodegenerative-neuromuscular disease.
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3.3 Material and Methods
Genetic studies
A cohort of 1293 presumed inherited myopathy patients was sequenced using a targeted highthroughput sequencing panel called MYOcap. The panel covered the exons, as well as some 3’
and 5’ UTRs of selected genes either reported to cause muscle disease, or genes functionally
related to such genes [6]. The MYOcap panel has been regularly updated and samples of the
cohort were sequenced with four versions covering 180, 236, 265 and 297 genes respectively.
Details are available upon request. The TIA1 and SQSTM1 genes were included in all versions.
Specific probes were manufactured by Roche NimbleGen (SeqCap EZ Choice Library). DNA
was extracted from blood by standard methods and enrichment, and sequencing was done at
FIMM, Biomedicum, Helsinki, Finland and at The Welcome Trust Centre for Human Genetics
(WTCHG) Oxford, England with the HiSeq1500 and 2000 platforms. The sequencing raw data
was mapped against the human reference genome GRCh37/hg19. Data analysis was performed
using an in-house pipeline as described earlier [6].
Indexed genomic DNA (gDNA) libraries were prepared from gDNA using TruSeq DNA
Preparation kit (Illumina, San Diego, CA) and exome capture using TruSeq Exome Enrichment
kit (Illumina, San Diego, CA) according to manufacturer’s protocol. Sequencing was performed
with 100bp paired-end reads on a HiSeq2000 (Illumina, San Diego, CA). Reads were aligned to
the human reference genome with NovoAlign or Burrows-Wheeler Aligner. Variants were called
with SAMtools and annotated with SeattleSeq. Coverage across genomic intervals was
calculated using BEDTools. Genomic coordinates for regions targeted by the whole-exome
capture kit were provided by Illumina. High-throughput sequencing results were verified by
Sanger sequencing. Primer sequences are available upon request.
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Allele frequencies for the general population were taken from gnomAD [110].
Protein purification, In Vitro Fibrilization, and phase diagram
Recombinant DNA for TIA1-WT, N387S, E384K constructs were cloned into pETite N-His
SUMO Kan vector (Lucigen Corporation). Plasmids were chemically transformed into
BL21_DE3 cells (Lucigen Corporation). Protein purification, In Vitro Fibrilization and phase
diagram protocols described in Mackenzie et al.[60] were followed. For phase diagram, the
spectrum of BSA (non-amyloid fibril forming) was measured as a baseline. That baseline has
been subtracted from all the WT, E384K and N357S spectra at each time point respectively.
Muscle pathology, reagent and antibodies
Frozen muscle sections were processed for routine histochemical staining, including
H&E, modified Gomori trichrome, combined succinate dehydrogenase–cytochrome oxidase,
ATPase at pH 9.2, pH 4.3 and reduced nicotinamide adenine dinucleotide–tetrazolium reductase.
Anti-TIA1 polyclonal antibody (SantaCruz #sc-1751, 1:500 for WB, 1:100 for IF), antiG3BP1 polyclonal antibody (Proteintech #13057-2-AP, 1:100 for IF), anti-p62 polyclonal
antibody (Proteintech #18420-1-AP, 1:1000 for WB, 1:100 for IF), anti-GFP polyclonal antibody
(Sigma #G1544, 1:500 for WB), anti-Ub monoclonal antibody (FK2; Biomol #PW-8810, 1:500
for WB, 1:100 for IF), anti-Ub polyclonal antibody (Dako #Z0458, 1:5000 for WB, 1:100 for
IF), anti-Gapdh polyclonal antibody (Cell Signaling #2118, 1:1000 for WB). For detecting
endogenous proteins in patient muscle biopsy, the following antibodies were used for IF: antiTIA1 polyclonal (Abcam ab61700, 1:100) and anti-p62 polyclonal (Sigma-Aldrich P0067,
1:100).
Cell culture and transient transfection
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Immortalized control and p62-/-MEFs were from Dr. Komatsu, Niigata University (Komatsu et
al., 2007). MEFs were maintained in in Dulbecco’s modified Eagle’s medium (DMEM, Gibco
#11965-084), 10% fetal bovine serum (FBS, Atlanta Biologicals #S10350H), and 50 μg/mL
penicillin and streptomycin (P/S, Sigma #P4333), 1% sodium pyruvate (Gibco #11360070), and
1% non-essential amino acid (Gibco #11140050) at 37°C with 5% CO2. C2C12 cells were
maintained in DMEM, 20% FBS, and 50 μg/mL P/S. Transfection was performed with
lipofectamine2000 (Life Technologies #11668019) according to the manufacturer’s instruction.
24hr post-transfection, cells were washed three times with ice-chilled PBS. pDEST-mCherryhuman p62 WT was gifted from Dr. Johansen, The Arctic University of Norway [18]. pDESTmCherry-human p62 P392L, M404V, A390X generated by mutagenesis. GFP-human TIA1 WT
(isoform A) has been previously reported and GFP-human TIA1 E384K and N357S were
generated by mutagenesis [60].
Immunocytochemistry and fluorescence microscopy
Cells were grown on glass coverslips prior to transfection with plasmid constructs. 24hrs after
the transfection, cells were washed three times with PBS, fixed in 4% PFA for 10mins and
permeabilized with 0.05% Triton X-100 in PBS for 10mins. After washing three times with PBS,
cells were blocked with 2% BSA in PBS for 30mins-1hr at room temperature (RT). Cells were
stained with primary antibody at 4°C overnight followed by three-times washing with PBS. Cells
were incubated with Alexa 555 or 488 Fluor-conjugated secondary antibody at RT for 1hr and
mounted with Mowiol media containing DAPI. 10 random fields were taken with 20x objective
equipped in a NIKON Eclipse 80i fluorescence microscopy. A blue channel was separated and
used to count the total number of DAPI-stained cells in Figure 3B, 5B and S3B. Cells co-stained
both with TIA1 (green) and G3BP1 (red) were counted in a merge channel. For Figure 2C-D and
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5A, individual cells shown in a green or red channel were considered as GFP-TIA1 or mCherrySQSTM1 expressing cells and counted as a total. GFP-TIA1 expressing cells stained with
SQSTM1 (red) or mCherry-SQSTM1 expressing cells stained with TIA1 (green) were manually
counted in a merge channel. For Figure5D, C2C12 cells expressing both mCherry-SQSTM1 and
GFP-TIA1 were counted as a total in each red or green channel while those C2C12 cells
containing GFP-TIA1 puncta were counted in a merge channel. In Figure 3C-D, individual SGs
puncta stained with TIA1 (green) were counted in a green channel as a total while TIA1 SGs colocalized with SQSTM1 (red) were counted in a merge channel. For Figure 4A-B and 4C-D,
individual endogenous TIA1 or GFP-TIA1 SGs puncta (green) were counted as a total in a green
channel while TIA1 SGs co-localized DRiPs (red) were counted in a merge channel. For Figure
4E-F, individual TIA1 puncta (green) were counted as a total in a green channel and TIA1/TDP43 positive puncta were counted in a merge channel. Cells or individual SGs puncta were
manually counted using ImageJ software (NIH). Frozen muscle biopsy sections (8 µm) were
prepared on slides, fixed in 4% PFA for 15 min and immunostained using similar protocol as for
cultured cells.
Heat Shock, inhibitor treatment and DRiPs labeling
MEFs cells or C2C12 cells were incubated at 42°C with 5% CO2 for 1hr and returned to 37°C
for the indicated time points. For AsIII (Sigma #38150) treatment, control MEFs cells were
treated with 0.5mM AsIII for 1hr and AsIII-containing media was replaced for the indicated time
point. To label DRiPs, control or p62-/- cells were incubated at 42°C with 5% CO2 for 1hr and
simultaneously treated with 25M op-PURO for 30mins. For recovery experiments, cells were
returned to 37°C and op-PURO-containing media was replaced for the indicated time. Fixation
and Click-iT reaction were performed with Alexa Azide 594 according to the manufacturer’s
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instruction (Life Technologies #C10399). MG132 (#C2211) and BafA (#B1793) were purchased
from Sigma. 20M MG132 or 200nM BafA were treated to control MEFs and p62-/-MEFs for
1hr at 37°C with 5% CO2 after 1hr HS at 42°C.
Fluorescence recovery after photobleaching
Control MEFs were grown on 1.5 Glass bottom 35mm dishes (MatTek #P35G-1.5-10-C) and
transfected with GFP-human TIA1 for 24hrs prior to imaging. Immediately before imaging, the
medium was replaced with Phenol Red-free medium (Gibco #21063029) containing 10% FBS,
50 μg/mL P/S, 1% sodium pyruvate, and 1% non-essential amino acid. The live cell samples
were treated with 0.5mM AsIII for 1hr and placed on a heated chamber at 37°C with 5% CO2.
The imaging and photobleaching were performed with 40x oil objective using an NIKON A1Rsi
confocal microscopy. Before bleaching, the images of pre-bleached TIA1 aggregates were taken.
488nm laser was used to photobleach TIA1 aggregates for 500ms. Immediately after the
bleaching, the images were collected every 1s for a total of 150seconds as a post-bleached
sample. The fluorescence intensities of post-bleached TIA1 aggregates (Ft) were individually
measured. In the meantime, the fluorescence intensities of non-bleached TIA1 aggregates were
measured as a reference control (Fref). Also, the fluorescence intensities of non-bleached and
non-transfected background were measured as a background control (Fb). The photobleaching
rate (r) was calculated by comparing the fluorescence of the reference before (Fref0) and after
(Fref) photobleaching. r= Fref/Fref0. An average of TIA1 aggregates fluorescence intensities (F)
in different cells (n≥5 cells containing TIA1 aggregates) was calculated as followed. F=(FtFb)/r.

LDH Assay
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C2C12 cells were transfected with Cherry-p62-WT, or AX along with GFP-TIA1-WT, NS, or
EK 24hrs prior to LDH assay. Cells were split into 96-well plate in 2x105 cells/well as triplicates.
Cells were incubated in 1hr at 42°C with 5% CO2 and returned to 37°C with 5% CO2 for 1hr
recovery. LDH assay was performed according to the manufacturer’s instruction (Roche #04 744
926 001).
Statistical analysis
A two-tailed Student’s t-test was performed. For all tests, p-values<0.05 were considered
statistically significant. Data are represented as mean ± SEM.
Study approval
All examinations and genetic studies were conducted according to approval of the Human
Studies Committee at Washington University and Helsinki University IRB and with informed
consent of the patients following the Helsinki declaration.

72

3.4 Result
3.4.1 Digenic inheritance of an MSP-associated SQSTM1 mutation with a rare
TIA1-N357S variant occurs in distal myopathy patients with rimmed vacuolar
pathology.
We have previously described two unrelated families with distal myopathy and RV-IBM
pathology due to a c.1165+1 G>A splice donor variant in SQSTM1 [75]. This variant generates a
truncated SQSTM1 protein that lacks its UBA domain and has been identified in patients with
PDB and ALS [3, 4]. Subsequent to this discovery, we identified an additional three patients with
a distal myopathy and a SQSTM1 p.P392L variant [6]. This SQSTM1 p.P392L variant has
similarly been associated with dominantly inherited PDB, ALS and FTD, phenotypes that were
not present in our patients [3-5]. Interestingly, these three patients had been previously identified
in our cohort of distal myopathy patients carrying a rare TIA1 c.1070A>G; p.N357S;
rs116621885 variant with a MAF 0.007. Surprisingly, our three previously reported SQSTM1
c.1165+1 G>A patients also carried the same rare TIA1 p.N357S variant. Dominant mutations in
TIA1 are associated with WDM, a distal myopathy with RV-IBM pathology, and more recently,
ALS and FTD [60, 61]. Notably, similar to the WDM and ALS/FTD associated TIA1 mutations,
the TIA1 p.N357S variant was present within the LCD at conserved residues (Figure 1A).
To identify more myopathy patients with SQSTM1 mutations and the TIA1 p.N357S
variant, we utilized two approaches. First, we analyzed our neuromuscular disease gene panel
sequencing results that included SQSTM1 and TIA1 in 1294 patients with a presumed hereditary
muscle disease [6]. In addition, we Sanger sequenced SQSTM1 in 14 undetermined distal
myopathy patients with a WDM phenotype that we had previously identified with TIA1 p.N357S
variant. These approaches identified a total of eight patients from six families with the common
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SQSTM1 p.P392L mutation of which seven also carried the TIA1 p.N357S variant. Notably, none
of them had PDB and all had a distal myopathy with RV-IBM pathology, with the exception of
one single patient that carried only the SQSTM1 p.P392L mutation without the TIA1 p.N357S
variant. This patient had a proximal phenotype without RV-IBM muscle pathology and had been
characterized as limb-girdle muscular dystrophy.
We also identified three patients from two families with a previously reported SQSTM1
p.M404V mutation that is associated with PDB and dementia [111, 112]. These patients also
carried the TIA1 p.N357S variant and had a late onset distal predominant myopathy with RVIBM pathology and no evidence of PDB. One additional distal myopathy with RV-IBM
pathology patient carried a rare synonymous SQSTM1 variant c.1083C>T, p.S361S that has been
previously identified in a patient with early onset dementia and the TIA1 p.N357S variant [112].
This synonymous mutation has a MAF of 0.00008 and is predicted to be disease causing.
MRI imaging of patients’ lower extremities demonstrated extensive fatty degenerative
changes in distal muscles shown by focal involvement of lower leg gastrocnemius and soleus
muscles in Figure 3.4.1C. Patient muscle biopsies demonstrated variation in fiber size and
rimmed vacuoles consistent with RV-IBM (Figure 1D and S1B). In pathologically normal
muscle, SQSTM1 is diffusely sarcoplasmic and TDP-43 and TIA1 are myonuclear (Figure S1A).
In contrast, SQSTM1 and TIA1 accumulate in patient muscle sarcoplasm and had some colocalization at RVs as determined by immunohistochemistry (Figure 1E). In addition, TIA1
accumulated with other RNA binding proteins such as TDP-43 and HNRNPA2B1 (Figure 1E
and S1C). Western blot analysis of skeletal muscle from one patient, found normal steady state
levels for SQSTM1 and TIA1 (Figure S1D). Table1 denotes the clinical and laboratory
characteristics for all SQSTM1-TIA1 patients included in this study. Digenic inheritance was
74

demonstrated in three families in which only examined affected family members carried both a
SQSTM1 p.P392L or a SQSTM1 p.M404V mutation and a TIA1 p.N357S variant whereas family
members carrying only a TIA1 p.N357S variant were unaffected (Figure 1B).
Importantly, sequencing of 50 patients (26 male, 24 female: average age 73.7+/-7.3years)
with previously reported pathogenic SQSTM1 mutations including 40 with a SQSTM1-P392L
mutation and two with a SQSTM1-M404V mutation manifesting with PDB but no muscle
weakness did not reveal any TIA1-N357S variant supporting that both variants are necessary for
a muscle phenotype with RV-IBM pathology (Supplemental Table S1) [113].
Although patients in these small pedigrees with only the TIA1 p.N357S variant had no
evidence of weakness, we reasoned that the rare TIA1 p.N357S variant may itself be enriched in
patients with a distal myopathy phenotype. Indeed, in our large sequencing project of 1293
presumed inherited myopathy patients, 41 (3%) had the N357S variant (allele frequency 0.0162
versus 0.007 in the general population), and when this was stratified to those with a distal
myopathy phenotype involving also upper limbs, 17/86 (20%) of these patients carried the
variant, including one patient that was homozygous for the TIA1 p.N357S variant making the
allele frequency 0.1 for distal myopathy. A similar overrepresentation of this TIA1 p.N357S
variant was seen in 5 patients from a second cohort of 51 undiagnosed myopathy patients
following whole exome sequencing. All 5 patients had a distal predominant phenotype with RVIBM pathology including two patients with an additional c.1165+1 G>A splice donor variant in
SQSTM1 [75].
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Figure 1. Digenic inheritance of SQSTM1 and TIA1 variants lead to a distal myopathy with RV-IBM
pathology. A) Linear diagram of TIA1 protein highlighting conserved regions of the LCD. Distal myopathy
associated variant positions are shown in yellow and ALS/FTD variants in blue. B) Pedigrees of families IV, VII
and IX showing segregation. DNA was only available for patients marked with *. C) Muscle imaging findings of
patient V-2 at age 54. Severe involvement of all calf muscles is seen on MRI T1-weighted images. Filled arrow
denotes normal muscle and open arrow indicates atrophic muscle with fatty replacement. D) H&E staining of a
muscle biopsy of the right tibialis from patient XII-1 showing several fibers with rimmed vacuoles (arrows). E)
Immunofluorescent staining of TIA1 (red) with SQSTM1 (green in upper panel) or TDP-43 (green in lower panel)
revealed accumulation and partial co-localization of these proteins in patient V-2 muscle biopsy. Both images show
a rimmed vacuolar fiber. Dotted line denotes affected fiber.
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Figure S1. Histopathology of SQSTM1-TIA1 patients and controls. A) Immunofluorescent staining of TIA1 (red
in upper panel) or TDP-43 (green) and SQSTM1 (green in lower panel). B) Serial sections from patient muscle
biopsy histochemically stained with hematoxylin and eosin (H&E) and Herovici staining demonstrating myopathy
with rimmed vacuoles. Immunohistochemistry of similar sections stained with antibodies against autophagic marker
LC3B and TDP-43. C) Co-immunofluorescent staining of patient muscle with antibodies to TIA1 (red) and
HNRNPA2B1 (green). D) Patient and control muscle immunoblot for TIA1 and SQSTM1. Myosin is shown as a
loading control.
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Table 1. Clinical characteristics of the patients. EDL/EHL, long toe extensors; Gmed, gastrocnemius medialis;
Glat, gastrocnemius lateralis; NA, not available; ND, not done; PNP, polyneuropathy; S, soleus; TA, tibialis
anterior; UNL, upper normal limit. Previously reported patients. *[75]**[6]
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Patient

Gender

Age

Onset

SQSTM1

TIA1 SNP

1

F

67

67

P392L/WT

WT/WT

2

F

71

56

G425R/WT

WT/WT

3

M

66

53

P392L/WT

WT/WT

4

F

83

63

P392L/WT

WT/WT

5

M

68

60

P392L/WT

WT/WT

6

M

59

56

G425R/I424S

WT/WT

7

F

69

55

G425R/WT

WT/WT

8

F

71

55

M404V/WT

WT/WT

9

F

74

47

P392L/WT

WT/WT

10

F

78

69

P392L/WT

WT/WT

11

F

81

49

P392L/WT

WT/WT

12

M

74

45

P392L/WT

WT/WT

13

M

74

64

P392L/WT

WT/WT

14

M

71

66

P392L/WT

WT/WT

15

F

69

50

M404T/WT

WT/WT

16

M

91

54

P392L/WT

WT/WT

17

M

72

58

P392L/WT

WT/WT

18

M

80

78

P392L/WT

WT/WT

19

F

62

54

G425R/WT

WT/WT

20

M

64

54

P392L/WT

WT/WT

21

F

67

48

P392L/WT

WT/WT

22

M

82

57

P392L/WT

WT/WT

23

M

76

72

P392L/WT

WT/WT

24

F

73

45

P392L/WT

WT/WT

25

F

72

67

P392L/WT

WT/WT

79

26

M

73

70

P392L/WT

WT/WT

27

M

89

60

P392L/WT

WT/WT

28

F

85

84

P392L/WT

WT/WT

29

M

83

54

E396X/WT

WT/WT

30

F

82

75

P392L/WT

WT/WT

31

M

72

26

I424S/WT

WT/WT

32

F

84

79

P392L/WT

WT/WT

33

F

74

64

M404V/WT

WT/WT

34

M

72

55

P392L/WT

WT/WT

35

F

86

76

P392L/WT

WT/WT

36

M

62

55

P392L/WT

WT/WT

37

M

75

63

P392L/WT

WT/WT

38

M

71

72

P392L/WT

WT/WT

39

F

80

70

P392L/WT

WT/WT

40

M

79

41

P392L/WT

WT/WT

41

F

70

70

P392L/WT

WT/WT

42

M

74

50

P392L/WT

WT/WT

43

F

67

54

P392L/WT

WT/WT

44

M

76

59

P392L/WT

WT/WT

45

F

59

51

P392L/WT

WT/WT

46

F

66

40

P392L/WT

WT/WT

47

F

78

52

P392L/WT

WT/WT

48

M

72

70

P392L/WT

WT/WT

49

F

71

66

P392L/WT

WT/WT

50

F

73

67

P392L/WT

WT/WT

Table S1. Genotypes of PDB patients.
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3.4.2 TIA1 N357S variant promotes LLPS and impairs stress granule
clearance.
To examine the impact of the TIA1-N357S (NS) mutation on LLPS, we constructed a phase
diagram by measuring the co-existence line of protein-depleted light phase and protein-enriched
dense phase as a function of temperature and protein concentration. Similar to the previously
characterized TIA1-E384K (EK) mutant, the TIA1-NS mutation caused a significant leftward
shift in the co-existence line to a lower protein concentration, indicating an increased propensity
of mutant TIA1 to phase separate, due to stronger intermolecular protein-protein interactions
(Figure 2A). Although the promotion of LLPS with TIA1-EK was associated with an increased
rate of amyloid-like fibril formation as demonstrated by a time dependent increase in thioflavinT incorporation when compared to TIA1-WT, this increase was not seen with purified TIA1-NS
(Figure 2B).
The effect of TIA1-NS and EK variants on LLPS in vitro suggested that these variants
might affect the dynamics of SGs in vivo. To test this hypothesis, we expressed GFP-TIA1-WT,
-NS, or -EK in mouse embryonic fibroblasts (MEFs) for 24hrs. Immunoblotting confirmed
similar levels of expression for GFP-TIA1-WT, -NS, or -EK (Figure S2A). MEFs expressing
GFP-TIA1 were fixed and stained with the SG marker, G3BP1. Individual GFP-TIA1 expressing
cells were considered as a total number of cells while cells containing GFP-TIA1/G3BP1 SGs
were counted. Untreated GFP-TIA1-WT expressing cells did not form SGs while some SGs were
detected in GFP-TIA1-NS or-EK expressing cells (Figure 2C-D). 42ºC heat shock (HS) induces
SG formation in MEFs expressing GFP-TIA1-WT, -NS, or -EK after 1 hour. Upon return to
37ºC for 30 minutes ~10% of GFP-TIA1-WT expressing MEFs contained SGs as compared to
~40% of MEFs expressing GFP-TIA1-NS or -EK (Figure 2C-D). TIA1 in SGs is normally in
rapid equilibrium with TIA1 in the surrounding cytoplasm. We investigated whether TIA1-NS
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mutation affects its mobility within SGs. MEFs expressing GFP-TIA1-WT, -NS, or -EK were
treated with 0.5mM arsenite (AsIII) for 1hr and GFP-TIA1 SGs were subject to fluorescence
recovery after photobleaching (FRAP). Following photobleaching, ~65% of GFP-TIA1-WT
fluorescence rapidly recovers whereas GFP-TIA1-NS and -EK recover to ~40 and 60%
respectively (Figure 2E and Figure S2B).
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Figure 2. TIA1 N357S variant promote liquid-liquid phase separation and disrupts stress granule dynamics.
A) Phase diagram TIA1-WT, EK and NS are mapped at physiological conditions. Mean concentration of light phase
(protein depleted phase) and SE are plotted. A quadratic equation is used to fit the trendlines (R2, WT and NS =
0.99, EK = 0.98, P<0.003 for NS vs WT and P<0.0002 for EK vs WT were obtained by chi-squared test). Insets
show characteristics DIC images of light, diffused phase and dense phase droplets respectively. Concentration of
light phase of NS variant at 5ºC was below detection limit. B) Fluorescence intensity of amyloid fibrils monitored
by Thioflavin T (ThT), in light phase regime at 2.5 µM of TIA1-WT, EK and NS variants taken. Samples were
agitated at RT for 24h. Each time point was measured, and mean and SE of mean, of ThT fluorescent intensity at
480 nm are plotted. The spectrum of BSA (non-amyloid fibril forming) was measured as a baseline. That baseline
has been subtracted from all the WT, EK and NS spectra at each time point respectively. *** denote p value <0.001.
C) Immunofluorescent images of mouse embryonic fibroblasts (MEFs) expressing GFP-TIA1-WT, NS, or EK
immunostained with anti-G3BP1 (red) prior to 1 hour heat shock (HS) at 42C, immediately post HS or following
30 minutes of HS recovery at 37C. Blue color indicates DAPI nuclear staining. Scale is 5µm. D) Bar graph of the
percentage of cells containing TIA1/G3BP1 positive stress granules under the conditions in (B). Representative data
were pooled from three independent experiments (n=150~200). E) Graphical representation of the average relative
fluorescent intensity (RFI) following photobleaching of individual SGs from MEFs expressing GFP-TIA1-WT, NS,
or EK and treated for one hour with 0.5mM arsenite. Representative data were pooled from three independent
experiments (n=20~30). All error bars are mean ± SEM, *P<0.05.

84

Supplemental Fig 2.
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Figure S2. Immunoblot images of GFP-TIA1 and live cell images following photobleaching. A) Immunoblot
from control MEFs expressing GFP-TIA1-Empty, WT, NS, or EK for GFP and SQSTM1. GAPDH is shown as a
loading control. B) Representative fluorescence images of GFP-TIA1-WT, EK, or NS stress granules from live
MEFs cells expressing GFP-TIA1, EK, or NS in (Figure 2E). The circle indicates the photobleached area. Scale is
1µm.
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3.4.3 SQSTM1 participates in stress granule protein clearance.
To explore the role of SQSTM1 in SG formation and clearance, we immunostained endogenous
TIA1 and G3BP1 in control MEFs and MEFs lacking SQSTM1 (p62-/-MEFs). Individual cells
were considered as a total number of cells while cells containing TIA1/G3BP1 SGs were
counted. Untreated control or p62-/-MEFs did not form TIA1/G3BP1 positive SGs (Figure 3AB). Following 1hr HS, ~95% of control MEFs and 70% of p62-/-MEFs contained SGs (Figure
3A-B). 20 mins after re-incubating cells at 37ºC, ~50% of SGs disappeared in control MEFs and
ultimately dissipated by one hour. In contrast, p62-/-MEFs had a slower SG clearance, with
some cells maintaining SGs after 180 minutes (Figure 3A-B). Persistent TIA1 positive SGs in
p62-/-MEFs co-immunolocalized with an antibody that recognizes ubiquitin conjugates (Figure
S3A). Consistent with SQSTM1 mediating the clearance of SGs via an autophago-lysosomal
pathway, we found that incubation of p62-/-MEFs with the lysosomal inhibitor BafilomycinA
during HS recovery did not further augment the decrease in SG clearance seen with loss of
SQSTM1 (Figure S3B).
To explore a direct connection between TIA1 and SQSTM1, we immunostained for
endogenous SQSTM1 in MEFs expressing GFP-TIA1-WT, -NS, or -EK after 1hr HS and
following 30 mins recovery to 37ºC. Individual GFP-TIA1 SGs puncta were considered as a total
number of SGs and the number of GFP-TIA1 SGs puncta co-localized with endogenous
SQSTM1 was counted at indicated time points. A subset of GFP-TIA1-WT SGs co-localized
with SQSTM1. The co-localization of SQSTM1 and GFP-TIA1 was greater in GFP-TIA1-NS or
-EK compared to GFP-TIA1-WT expressing MEFs (Figure 3C-D).
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Figure 3.
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Figure 3. SQSTM1 is necessary for stress granule homeostasis. A) Immunofluorescent images of control or
SQSTM1 knockout MEFs (p62-/-), incubated at 42C for 1hr and returned to 37C for indicated times, and
immunostained for TIA1 (green) and G3BP1 (red) to detect SGs. B) Graph of the percentage of cells containing
TIA1/G3BP1 positive stress granules in (A). Transfected cells were counted and indicated as a total number of cells.
Representative data were pooled from three independent experiments (n=150~200). C) Immunofluorescent images
of MEFs expressing GFP-TIA1-WT, NS, or EK and immunostained with SQSTM1 antibody following incubation at
42C for 1hr and re-incubated at 37C for indicated time. D) Graph of the percentage of GFP-TIA1/SQSTM1
positive SGs puncta in (C). Individual GFP-TIA1 SGs puncta were counted and indicated as a total number of SGs.
Representative data were pooled from three independent experiments (n=800~1000). Scale is 5m and error bars are
mean± SEM for all figures. *P<0.05.
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Supplemental Fig 3.
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Figure S3. Immunostaining of stress granules accumulating ubiquitin conjugates and bar graph of cells
treated with proteasomal inhibitor (MG132) or lysosomal autophagic inhibitor (BafilomycinA). A)
Immunofluorescent images of control or p62-/- MEFs for TIA1 and ubiquitin (FK2) before HS, after incubation at
42C for 1hr and following 30 min HS recovery. Representative data were pooled from three independent
experiments (n=150~200). Blue color indicates DAPI staining. B) Bar graph of the percentage of MEFs cells
containing TIA1/G3BP1 positive SGs. Control of p62-/- MEFs were incubated at 42C for 1hr (HS). They were
subsequently returned to 37C and incubated with DMSO, MG132, or BafilomycinA for 1hr. All error bars are
mean ± SEM. * denotes p value <0.05.
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3.4.4 The presence of aggregated proteins increases TIA SG persistence in the
presence of TIA1 mutations or loss of SQSTM1.
Defective ribosomal products (DRiPs) are prematurely terminated and/or misfolded polypeptides
[73, 114]. They may form transient inclusions that co-localize with SQSTM1 and are targeted for
clearance via the proteasome or autophagy [73, 114-116]. DRiPs may also accumulate adjacent
to and within SGs, which may lead to altered SG kinetics [73, 114]. To see if SQSTM1 mediates
the clearance of DRiP-containing SGs, we treated control and p62-/-MEFs with OP-puromycin
to generate and label DRiPs. Individual TIA1 positive SGs puncta were considered as a total
number of SGs and the number of TIA1 SGs puncta stained with DRiPs were counted. After 1hr
HS, ~30% of SGs co-localized with DRiPs in control MEFs and ~45% of SGs co-localized with
DRiPs in p62-/-MEFs (Figure 4A-B). Surprisingly, after 30mins of HS recovery, DRiP
containing SGs significantly decreased in control MEFs but DRiP containing SGs accumulated
in p62-/-MEFs, suggesting that the clearance of aberrant SGs with DRiPs is SQSTM1-dependent
(Figure 4A-B). Similarly, we treated MEFs expressing GFP-TIA1-WT, -NS, or -EK with OPpuromycin to generate and label DRiPs as above. Following 1 hr HS, ~35% of GFP-TIA1-WT
SGs co-localized with DRiPs, this number decreased upon HS recovery (Figure 4C-D). In
contrast, GFP-TIA1-NS and –EK SGs co-localized more robustly with DRiPs following HS and
this association persisted upon HS recovery (Figure 4C-D).
We reasoned that since DRiPs were misfolded proteins, TIA1 may similarly accumulate
with other misfolded and aggregated proteins at SGs. To test this, we expressed an aggregation
prone 25kDa C-terminal TDP-43 fragment with an mCherry tag (mCherry-TDP-CTF) in control
or p62-/- MEFs and subjected them to 1 hr HS followed by 30 minutes of recovery. Individual
TIA1 positive SGs puncta were considered as a total number of SGs and the number of TIA1
SGs puncta co-localized with mCherry-TDP-CTF was counted. Immunofluorescence for
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endogenous TIA1 found that upon HS, TIA1 and mCherry-TDP-CTF co-localized in both cell
types (Figure 4E-F). However, upon recovery in the p62-/- MEFs, ~80% of persistent TIA1
positive SGs also contained mCherry-TDP-CTF as compared with ~20% in control MEFs
(Figure 4E-F).
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Figure 4. The presence of aggregated proteins increases TIA SG persistence in the presence of TIA1
mutations or loss of SQSTM1. A) Immunofluorescent images of control or p62-/-MEFs expressing labeled with
Alexa594-Azide (red) to detect DRiPs after incubation at 42C for 1hr and following 30 min HS recovery.
Representative data were pooled from three independent experiments (n=350~450). B) Graph of the percentage of
TIA1 SGs puncta labeled with Alexa594-Azide (red) that detect defective DRiPs in control or SQSTM1 knockout
MEFs (p62-/-), incubated at 42C for 1hr and returned to 37C for 30 minutes. Individual TIA1 SGs puncta (green)
were counted and indicated as total number of TIA1 SGs. Representative data were pooled from three independent
experiments (n=350~450). C) Immunofluorescent images of MEFs expressing GFP-TIA1-WT, NS, or EK and
labeled with Alexa594-Azide (red) to detect DRiPs before HS, after incubation at 42C for 1hr and following 30
min HS recovery. Representative data were pooled from three independent experiments (n=350~450). D) Graph of
the percentage of TIA1 SGs puncta labeled with DRiPs in (C). Individual TIA1 SGs puncta (green) were counted
and indicated as a total number of TIA1 SGs. E) Immunofluorescent images of endogenous TIA1 (green) from
control or p62-/-MEFs transfected with an mCherry tagged TDP-43 C-terminal fragment (red) after incubation at
42C for 1hr and following 30 min HS recovery. Representative data were pooled from three independent
experiments (n=350~450). F) Graph of the percentage of TIA1 SGs puncta with mCherry TDP-43 c-terminal
fragment in control or p62-/-MEFs from (E). Individual TIA1 SGs puncta (green) were counted and indicated as a
total number of TIA1 SGs. Blue color indicates DAPI nuclear staining. Scale is 5m and error bars are mean± SEM
for all figures. *P<0.05.
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3.4.5 MSP associated SQSTM1 mutations impair TIA1 positive stress granule
homeostasis.
To investigate whether SQSTM1 disease mutations identified in MSP patients affected the
clearance of TIA1-containing SGs, MEFs expressing mCherry, mCherry-SQSTM1-WT, or
mCherry-SQSTM1 carrying an MSP mutation, SQSTM1-P392L (PL), SQSTM1-M404V (MV),
or SQSTM1-A390X (AX) were immunostained with antibodies to endogenous TIA1. Without
HS, MEFs expressing mCherry or mCherry-SQSTM1-WT did not form SGs (Figure 5A). In
contrast, even without HS, MEFs expressing mCherry-SQSTM1 disease mutations (PL, MV, or
AX) had TIA1 positive SGs (Figure 5A). As expected, most cells contained SGs following 1
hour HS and after 30 min post HS recovery, ~50% of SGs were cleared in MEFs expressing
mCherry or mCherry-SQSTM1-WT. In contrast, following 30 mins HS recovery, MEFs
expressing mCherry-SQSTM1-PL, -MV, or –AX had persistent SGs in 80% of cells, suggesting
that disease-associated SQSTM1 mutations delay SG clearance (Figure 5A).
To explore the synergy of a SQSTM1 disease mutation and the TIA1-N357S variant, we
utilized patient derived fibroblasts from two control patients (#112, #409), two patients carrying
the TIA1-N357S variant (#107, #319) and one patient carrying both a SQSTM1 c.1165+1 G>A
mutations which generates a truncated SQSTM1-A390X mutation and a TIA1-N357S variant
(#483). We treated low passage fibroblasts with 0.5mM AsIII for 1hr and then replaced AsIIIcontaining media for 40 minutes. Fibroblasts were immunostained for endogenous TIA1 and
G3BP1. Untreated fibroblasts had no detectable SGs. Following one hour of AsIII treatment, all
fibroblasts formed TIA1/G3BP1 positive SGs (Figure 5B-C). These SGs dissipated in all
fibroblasts but were significantly increased in fibroblast line #483 that contains both disease
variants (Figure 5B-C).
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Figure 5. SQSTM1 disease mutations alter SG kinetics and synergistically mediate myotoxicity with TIA1N357S. A) Bar graph of the percentage of MEFs cells containing endogenous TIA1 positive SGs. MEFs were
transfected with mCherry, mCherry-SQSTM1-WT, or one of three different disease mutations (PL, MV or AX)
incubated at 42ºC for one hour and subsequently returned to 37ºC for the indicated time. Transfected cells were
counted and indicated as total number of cells. Representative data were pooled from three independent experiments
(n=450~550). B) Bar graph of the percentage of fibroblasts containing TIA1/G3BP1 positive SGs from the
fibroblasts of control patients (#112, #409), patients carrying the TIA1-N357S variant (#107, #319) and a patient
carrying both a SQSTM1-A390X mutation and a TIA1-N357S variant (#483) immediately following 0.5mM
Arsenite (AsIII) treatment for one hour or following 40 mins of recovery. C) Immunofluorescent images of patient
fibroblasts detailed in (B) immunostained with TIA1 (green) and G3BP1 antibodies (red) before, immediately
following 0.5mM AsIII treatment for one hour or following 40 mins of recovery. Blue color indicates DAPI nuclear
staining. Scale is 5m. Representative data were pooled from three independent experiments (n=120~150). D) Bar
graph of the percentage of C2C12 myoblasts containing TIA1 positive SGs. C2C12 myoblasts were co-transfected
with mCherry, mCherry-SQSTM1-WT or mCherry-SQSTM1 with one of three different disease mutations (PL, MV
or AX) and GFP-TIA1-WT or one of two variants (EK or NS) incubated at 42ºC for one hour and subsequently
returned to 37ºC for the indicated time. E) Bar graph of LDH release from C2C12 myoblasts similar to those in (D)
before HS and following 1hr HS with an additional 1hr recovery at 37C. The absorbance of the samples was
measured at 492nm. The reference wavelength at 680nm was measured. Representative data were pooled from three
independent experiments (n=150~200) and error bars are mean± SEM for all figures. * denotes p value <0.05.
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3.4.6 Co-expression of MSP associated SQSTM1 mutations and TIA1-N357S
is myotoxic.
To see if the synergistic effect of SQSTM1 mutations and TIA1 variants occurred in muscle cells,
we co-transfected C2C12 myoblasts with plasmids expressing mCherry-SQSTM1-WT, or
mCherry-SQSTM1 carrying an MSP mutation (PL, MV, or AX) and GFP-TIA1-WT or GFPTIA1 carrying a distal myopathy variant (EK or NS). Following 60 min HS, ~100% of myoblasts
had TIA1-GFP positive SG regardless of mutation or variant (Figure 5D). In contrast, after 60
min of HS recovery, myoblasts expressing a disease associated SQSTM1 mutation with a TIA1
variant had an increase in persistent SGs as compared with mCherry-SQSTM1-WT expressing
myoblasts (Figure 5D). To see if co-expression of SQSTM1-AX and TIA1-NS synergistically
enhanced myotoxicity, we performed a lactate dehydrogenase (LDH) release assay on C2C12
myoblasts co-transfected with plasmids expressing mCherry-SQSTM1-WT, or mCherrySQSTM1-AX and GFP-TIA1-WT or GFP-TIA1-NS before HS and following 60 min HS with
an additional 60 min HS recovery a timepoint when persistent SG are present. Consistent with a
synergistic effect, SQSTM1-AX and TIA1-NS expressing myoblasts had an increase in LDH
release as compared with SQSTM1-WT or TIA1-WT transfectants (Figure 5E).
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3.5 Discussion
The present study identified fourteen patients from nine families with a distal myopathy and RVIBM pathology that all carried a previously reported pleotropic mutation in SQSTM1 and a rare
TIA1-N357S variant. These patients did not manifest other phenotypes associated with SQSTM1
mutations such as PDB, ALS or FTD at the time of examination. Importantly, SQSTM1 and
TIA1 accumulated with TDP-43 in patient muscle tissue suggesting they participate in disease
pathogenesis. While the connection between SG clearance and autophagic protein degradation
has been previously suggested, the present study provides human genetic evidence for a
pathologic interaction [73, 109]. These data support that inheritance of a TIA1 variant can shift
the phenotypic spectrum of SQSTM1 mutations to myodegeneration.
Mutations in SQSTM1 were initially identified in patients with familial PDB and included
the SQSTM1-P392L and c.1165+1 G>A splice acceptor mutations [3]. Notably the SQSTM1P392L mutation was found in ~9% of sporadic PDB patients making it the most common genetic
cause of PDB [3]. Later reports identified other missense mutations in or truncations of
SQSTM1’s UBA domain including the M404V mutation as causative in familial and sporadic
PDB [111]. Subsequently, SQSTM1 mutations including the P392L and c.1165+1 G>A were
identified in patients with familial ALS and FTD [4, 5, 117]. In 2015, we described three patients
with a distal myopathy and RV-IBM pathology with the SQSTM1 c.1165+1 G>A mutation [75].
Since the same SQSTM1 mutation can generate distinct phenotypes in different patients, we
suggested that SQSTM1-associated disease be termed multisystem proteinopathy type 4 (MSP4)
[75]. MSP defines a pleotropic genetic disease in which a single gene and mutation can manifest
with distinct disease phenotypes that include PDB, RV-IBM, ALS and FTD.
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We previously reported a TIA1-E384K founder mutation as the cause of WDM, an
autosomal dominant distal myopathy with RV-IBM pathology [61]. The phenotype of WDM
patients is similar to the SQSTM1-TIA1 patients described in this report. WDM is a progressive
late onset myopathy that typically manifests in the fifth decade. Rare WDM patients that are
homozygous for the TIA1-E384K variant have an earlier onset and more rapid disease
progression suggesting that the TIA1-E384K mutation exerts a dose dependent dominant effect
[118]. Similarly, we identified one patient in our cohort with a distal myopathy that was
homozygous for the TIA1-N357S variant. This patient did not have a second mutation in
SQSTM1. The TIA1-N357S was overrepresented in our myopathy cohort and was present in 20%
of our distal myopathy patients. These data support that the TIA1-N357S may itself be a risk
factor for distal myopathy.
The findings in our study may relate to other forms of MSP. Specifically, mutations in
VCP, a ubiquitin segregase necessary for autophagic protein degradation, were the first identified
cause of MSP (originally termed IBMPFD for inclusion body myopathy associated with Paget’s
disease of the bone and fronto-temporal dementia) [97]. Recent studies confirm the original
report that 90% of patients develop RV-IBM, 42% PDB, 30% FTD but also expands the
degenerative phenotypes to include 9% with ALS and 4% with parkinsonism [119]. Why some
patients with VCP mutations develop RV-IBM and others PDB is not clear, but similar to our
study likely relates to oligogenic inheritance. For example patients manifesting with VCP
associated dementia are more likely to carry an APOE4 allele [120]. Some VCP mutations, like
the SQSTM1-P392L mutation have low minor allele frequencies in the general population. Rare
variants in VCP and SQSTM1 are identified as overrepresented in large cohorts of sporadic PDB,
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IBM, ALS and dementia patients suggesting that they may be risk factors for disease or have
reduced penetrance [4, 5, 112, 121-125].
Digenic inheritance can manifest in several ways. For example, the inheritance of second
genetic variant can affect the primary genes mutant phenotype by modifying its severity or age
of onset. Another example occurs when a single genetic mutation may have a reduced penetrance
and the inheritance of a mutation in a second gene unmasks the variable expressivity of the
primary mutation. Examples of true digenic inheritance in which the inheritance of two variants
on two different genes are necessary to manifest disease are rare and challenging to prove. One
recent example is in some forms of facioscapulohumeral muscular dystrophy type 2 (FSHD2)
where a patient must inherit both a permissive D4Z4 allele and an SMCHD1 variant on different
chromosomes [126]. The strength of this example relates to its presence in multiple families and
the convincing mechanistic interaction between the two alleles.
While autophagy has been implicated in SG clearance, this is the first report to
demonstrate a role for SQSTM1 in SG dynamics. RNA binding proteins such as TIA1 initiate
granule formation via their LCDs by promoting reversible LLPS [127]. Persistent SGs may
occur when LLPS converts the LCD into an irreversible amyloid like structure [67]. Our data
suggests that while the TIA-EK and NS variants promote phase separation, only the TIA1-EK
variant enhances its amyloidogenic conversion. This may explain why heterozygous TIA1E384K mutations lead to WDM yet TIA1-N357S variants require a SQSTM1 mutant
environment for penetrance. Loss of SQSTM1 or SQSTM1 mutant expression leads to the
accumulation of undegraded, ubiquitinated and insoluble proteins [18]. The presence of
misfolded and aggregate prone proteins increases SG formation and persistence in cell culture
[72, 114]. We similarly found that in the setting of SQSTM1 knockout or mutant expression,
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TIA1 persistent SGs co-localized with aggregated proteins such as DRiPs and a C-terminal TDP43 fragment. While it is possible that SQSTM1 directly shuttles ubiquitinated and aggregated
TIA1 to the autophagosome, we propose an alternate model. Specifically, the presence of
SQSTM1 mutations leads to the cytosolic accumulation of aggregated proteins that then serve as
a nidus for RNA granule conversion to an irreversible state.
The mechanism whereby disturbances in RNA granule dynamics and persistence of
poorly-dynamic SGs impair cell function in general or cause muscle degeneration in particular
remains unclear. One possibility is that disturbance of the SG dynamics results in impairment of
functions normally conducted within these complex membrane-less organelles (e.g. remodeling
of mRNPs or participating in intracellular signaling cascades). Alternatively, the condensed
liquid environment of the SG may promote untoward fibrillization of RNA-binding proteins to
produce insoluble, pathological species. Indeed, in vitro LLPS promotes rapid fibrillization of
RNA-binding proteins that occurs within the condensed liquid phase, resulting in the
accumulation of potentially toxic species [67].
An enigmatic feature of the syndrome MSP and most of the constituent diseases (ALS,
FTD and RV-IBM) is the prominence of TDP-43 pathology despite tremendous heterogeneity in
genetic etiology. Thus, mutations in genes as diverse as VCP, SQSTM1, C9ORF72, HNRNPA1,
HNRNPA2B1, TARDBP and TIA1 culminate in highly similar histopathology in which
cytoplasmic deposition of fibrillar TDP-43 is a prominent feature. Notably, even when disease
mutations occur in other RNA-binding proteins prone to fibrillization, such as TIA1, the
histopathological picture is dominated by TDP-43 pathology [60]. A likely explanation for this
phenomenon is differences in the stability of fibrils assembled from various RNA-binding
proteins. Indeed, it was recently demonstrated that recruitment of TDP-43 to SGs results in
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abrupt reduction in mobility of this protein and conversion to an SDS-resistant, poorly soluble
species, whereas other RNA-binding proteins recruited to the same SGs remain mobile and
soluble [60].
Cytosolic TDP-43 accumulation has been demonstrated to elicit cellular toxicity via
several mechanisms including disruptions in RNA transport, splicing and nucleocytoplasmic
shuttling [128]. Interestingly, autophagic inhibition leads to the cytosolic accumulation in TDP43 [129]. This effect also occurs in differentiated skeletal muscle, further connecting autophagic
impairment with SG pathology [129]. Interestingly, enhancing autophagy has been demonstrated
to be protective in the setting of TDP-43 accumulation [130].
MSP may represent an alternative manifestation of digenic inheritance. Specifically, a
mutation on gene X (i.e. SQSTM1 or VCP) can lead to variable expressivity of multiple
phenotypes (PDB, ALS, FTD or RV-IBM). Inheritance of a variant on gene Y (TIA1) while
impenetrant alone, dictates the phenotypic expression of gene X (distal myopathy with RV-IBM
pathology). This model explains the genetics of MSP but may also relate to the phenotypic
penetrance seen within the ALS-FTD spectrum. In addition, our model supports a
pathomechanistic connection between stress granule homeostasis and ubiquitin mediated
autophagic degradation.
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Chapter 4: General Conclusion and Future
direction
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4.1 The butterfly effect of a small protein, ubiquitin.
Minor perturbation in a small state such as the flapping of wings of a distant butterfly can cause a
major disruption in a large state, a tornado formation. This present dissertation showed that a
small change on a protein (ubiquitination on SQSTM1) can alter a cellular event (protein
degradation). This work demonstrated that SQSTM1 is regulated via its UBA domain
ubiquitination. In addition, K420 within UBA domain is ubiquitinated by Keap1/Cul3 E3 ligase
complex. Deletion of UBA domain or substitution of K420 to arginine decreases its
ubiquitination, decreasing the size of SQSTM1 bodies, the number of ubiquitinated inclusion
bodies, the interaction with LC3B, and the cell viability against ubiquitinated aggregates. The
overexpression of Keap1/Cul3 increases the size of SQSTM1 bodies and enhances the formation
of ubiquitinated inclusion bodies. Also, this increases the association with LC3B, consequently
the degradation of SQSTM1. Keap1/Cul3 overexpression can rescue cell viability against
proteotoxicity. Therefore, this dissertation proposed a model that SQSTM1’s UBA domain
ubiquitination by Keap1/Cul3 E3 ligase enhances its sequestering activity, recruits phagophores,
and subsequently increases the degradation of SQSTM1 bodies (Figure1).
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Figure 1. UBA domain ubiquitination regulates SQSTM1’s functions.
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Cellular functions of high-ordered structures have been emphasized. Post-translational
modification on high-ordered structure is one of common regulatory mechanisms [54]. This
work also parallels to this idea that ubiquitination within the UBA domain can modulate the
dynamics of high-ordered SQSTM1 oligomers. The SQSTM1 oligomers would sequester
ubiquitinated proteins and initiate the assembly of phagophore membranes, degrading the
substrates. It becomes clear that different E3 ligases regulate the structure and function of
SQSTM1, but how these E3 ligases cross talk to fine tune SQSTM1’s oligomerization and
functions still remains elucidated. It is possible that ubiquitination at different lysines of
SQSTM1 can be regulated in a cargo-depending manner. Parkin is a stereotypical mitophagy E3
ligase, which ubiquitinates the outer surface of mithochondria along with the PB1 domain of
SQSTM1 [36]. In contrast, upon oxidative stress, TRIM21 ubiquitinates the PB1 domain of
SQSTM1 to inhibit its sequestering activity [37]. The other remaining question is how
ubiquitination selectively regulates the SQSTM1’s interaction with other autophagy adaptor
proteins such as NBR1, OPTN and NDP52 upon different cargoes. To this end, which autophagy
adaptors are recruited to specific cargoes such as mitochondria, ubiquitinated protein aggregates
will be examined by utilizing genome-edited cell lines to knock out multiple autophagy adaptors.
For controls, ATG5-/-cells and single autophagy adaptor-knockout cells will be used.

4.2 Ubiquitination status of SQSTM1 disease mutants as a
unifying disease feature
This work seeks to answer a question: how do dominantly inherited SQSTM1 disease mutations
contribute to MSP pathogenesis? Most of identified SQSTM1 mutations are clustered within its
UBA domain. Along with the previous report on ubiquitin binding affinity of SQSTM1 mutants,
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we suggest that the reduced ubiquitination status of SQSTM1 mutants may be a unifying feature
of pathogenesis with reduced ubiquitin binding affinity [76]. Purified SQSTM1-K420R
decreases its binding to ubiquitin in vitro compared to naïve SQSTM1-WT while the c-terminus
of SQSTM1 enhances its binding to ubiquitin in vitro, suggesting the loss of ubiquitination
disrupts the ubiquitin binding [39]. Additionally, this study demonstrated that the ubiquitin
binding of UBA domain may be linked to its dimerization and ubiquitination. Purified SQSTM1K420R/E409A, which is neither ubiquitinated nor dimerized, binds much more strongly to
ubiquitin than any other purified SQSTM1 proteins. This finding supports our model that once
UBA domain ubiquitination at K420 would disrupt its dimerization with a neighboring UBA
domain, SQSTM1 forms its “open” SQSTM1 body structure, allowing increased ubiquitin
binding. However, it is not clear whether SQSTM1 disease mutants or SQSTM1-K420R are still
dimerized and remain as a “close” structure to bind less effectively to ubiquitin. To answer this,
in vitro structural studies such as Cryo-EM of purified SQSTM1-K420R and other disease
mutants in absence/present with ubiquitin should be continued.
Generating a MSP-mouse model can further expand our understanding on MSP diseases.
From our own lab, we are pursuing to generate muscle-specific VCP knock-out mouse model as
well as neuron-specific VCP knock-out mouse model. We hope to understand the function of
VCP and how its mutation manifests MSP in a tissue-specific manner by virally introducing a
VCP disease-causing mutation. Homogeneous population of muscle cells or neuronal cells from
these models will be isolated and analyzed. For controls, homogenous population of non-MSP
affected tissues will be analyzed. Also, several time points to isolate the tissues will be
considered since aging is one of the major risk factors of MSP and related to increased somatic
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mutations in post-mitotic cells [131]. Along with this work, SQSTM1 mouse models can be
generated and analyzed in parallel.
All SQSTM1 disease mutants showed decreased their sequestering function and cell
viability against proteotoxicity. Interestingly, the overexpression of Keap1/Cul3 in SQSTM1disease mutant transfected cells rescued cells against polyglutamine toxicity, suggesting that
SQSTM1’s UBA domain ubiquitination modulates selective autophagy and further connects to
SQSTM1 to Keap1-Nrf2 signaling. SQSTM1 mutations from ALS and FTD patients were
identified in KIR domain, showing the loss of binding to Keap1 and reduced Nrf2 activity [94].
Notably, Nrf2 activation can be cytoprotective in several diseases including neurodegenerative
disease, liver disease, and cancer [96, 132, 133]. Also, a recent study reported that chemical
modulation of Keap1 can selectively drive mitophagy [134]. This chemical treatment disrupts the
Keap1 association with Nrf2, allowing the Nrf2 translocation and accumulation in the nucleus.
Nrf2 then activates one of its target genes, SQSTM1 and SQSTM1is subsequently recruited to
damaged mitochondria along with other autophagic machinery proteins [45]. This compound
does not disturb general macro-autophagy process, but only targets damaged mitochondria. This
compound has not been tested in MSP-disease model, but it will be reasonable to administer this
chemical to examine the effect on SQSTM1 ubiquitination and protein aggregates clearance.

4.3 SQSTM1 mediates the clearance of SGs.
This present dissertation also provides genetic evidence that TIA1 variants can shift the
phenotype spectrum of SQSTM1-driven MSP to myodegeneration. 14 patients with RV-IBM
and distal myopathy from 9 families were identified to have both TIA1 and SQSTM1 mutations.
These patients did not manifest other phenotypes of MSP such as ALS, FTD, or PDB. One
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important note is that, 50 PDB patients carrying SQSTM1-P392L mutation do not have a TIA1
mutation and show no muscle weakness or any other relevant myopathy symptoms. However,
what drives other phenotypes of SQSTM1-mediated MSP such as ALS, FTD, and PDB is still
unclear and other digenic inheritance may explain this. More genetic studies in SQSTM1mediated ALS, FTD and PDB should be continued to answer this question.
Together with human genetic data, this dissertation shows that SQSTM1 is linked to both
systems: protein quality control (autophagy) and RNA quality control (SGs homeostasis) are
connected. The specific mechanism of SGs homeostasis still remains unclear but several studies
suggest that chaperones and autophagy machineries participate in this process as a part of their
protein-quality control (PQC) functions [109, 114]. However, with MSP-protein mutations
and/or under stress conditions, the PQC machineries are overwhelmed and SGs accumulate with
misfolded proteins such as TDP-43 in the cytosol. This brings up an important question: what
triggers persistent SGs formation and converts them into pathological aggregates? An intriguing
hypothesis is that the presence of aggregation-prone proteins in SGs promotes LLPS and the
formation of persistent SGs, irreversibly converted into pathological fibers. Also, this might
create a condensed environment for locally recruiting and accumulating more aggregation-prone
proteins such as TDP-43 to amplify the whole aggregation process.

4.4 Proposed model of SGs homeostasis
Aggregated proteins on SGs have been speculated as one of the major LLPS driving factors,
which generate persistent SGs. Mateju et al. reported that SGs co-assembles with SOD1,
promoting LLPS and generating poor-dynamic SGs [72]. Interestingly, after SOD1 mutants
accumulate within SGs, these mutants also become immobile. The previous study from
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Mackenzie et al. suggests that the TDP-43 pathology commonly seen in MSP-affected tissues
can be explained by this hypothesis. ALS/FTD-causing TIA1 mutations enhance LLPS and the
formation of persistent SGs, and accumulate with TDP-43, which becomes insoluble. In vitro
LLPS studies also supports that increased LLPS produces pathological SGs [67]. In contrast, a
chaperone complex, HSPB8/BAG3/HSP70, is recruited to SGs and aids to disassemble SGs
[114]. Inhibition or depletion of this complex disrupts the disassembly of SGs, which contain
aggregated proteins such as FUS. A recent interactome study also supports this interaction
between aggregation-prone proteins, SGs, and the PQC machineries [135]. The proteomic
analysis of polyglutamine repeat of Huntingtin mutants (HttQ) showed that most of soluble HttQ
interactors are RNA-binding proteins containing the LCD domain. Surprisingly, once soluble
HttQ oligomers become insoluble, they are less interactive and only small number of chaperones
and cochaperones e.g. DnaJB can access to these insoluble HttQ, preventing aberrant interaction
between HttQ oligomers and others. Similarly, Shorter group reported that Hsp104 solubilizes
and disassembles SGs containing RNA-binding proteins such as FUS or TDP-43 [136].
Here, we proposed an extended model of SGs homeostasis (Figure2). 1. Aggregationprone proteins accumulate within SGs. 2. E3 ligases such as TRIM21, TRIM25 interacting with
VCP catalyze these aggregated proteins [137, 138] 3. VCP and its cofactor segregate these
ubiquitianted proteins from SGs and shuttle them to the PQC machineries for their re-folding or
degradation, while SGs are disassembled by a chaperone complex, HSPB8/BAG3/HSP70. 4.
However, if the segregation or disassembly of SGs is failed, SQSTM1 recognizes and sequesters
these aberrant SGs with ubiquitinated proteins into inclusion bodies. 6. Aberrant SGs are
degraded via autophagy.
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We will further investigate whether VCP-recruited SGs fails to be cleared in p62-/-MEFs.
VCP is recruited to SGs upon heat shock, but the depletion or chemical inhibition of VCP
accumulates SGs with misfolded proteins e.g. TDP-43 and DRiPs, suggesting that VCP mediates
the disassembly and/or clearance of SGs [73, 109]. To this end, p62-/-MEFs and control MEFs
will be incubated for 1hour at 42°C for heat shock, and returned to 37°C for their recovery. Cells
will be co-stained with TIA1, G3BP (for SGs detection), and VCP. TIA1/G3BP1-positive SGs
will be counted as a total number of SGs and VCP/TIA1/G3BP1-positive SGs will be counted.
Whether the inhibition of VCP accumulates aberrant SGs (SGs containing ubiquitinated
proteins) together with SGs (SGs without ubiquitinated proteins) will be further examined.
Different VCP chemical inhibitors such as DBeQ, ML240 and EeyarestatinI will be treated in
p62-/-MEFs and control MEFs along with heat shock. Mock-treated cells and chaperone
inhibitor e.g. VER-155008 treated cells will be used as controls [72, 109, 114]. Cells will be costained with SGs markers, VCP, and ubiquitin. The expected result is shown in Figure3.
We expect that chaperones inhibitor-treated p62-/-MEFs will accumulate more SGs
without ubiquitianted proteins compared to mock-treated p62-/-MEFs since chaperone-mediated
SGs disassembly will be failed after VCP and its cofactors remove ubiquitianted proteins from
SGs. We also expect that VCP inhibitor-treated p62-/-MEFs will accumulate both SGs (SGs
without ubiquitinated protiens) and aberrant SGs (SGs with ubiquitinated proteins). To avoid offtarget effect of the chemical inhibitors, VCP siRNA can be utilized. Also, the inhibition of VCP
may disrupt the recruitment of E3 ligase catalyzing misfolded proteins within SGs. In this case,
we will examine TDP-43, FUS, or DRiPs accumulation within SGs instead of ubiquitinated
proteins.

110

We will further confirm this in MSP-disease models. Cells carrying MSP-disease
mutation accumulate VCP-recruited SGs [109]. In human fibroblast with disease-causing TDP43 mutations, SGs were persistent with recruited chaperone complexes [114]. We hypothesize
that VCP-recruited SGs also contain SQSTM1 along with chaperone complexes. To test this, we
will utilize U2OS cells expressing disease-causing VCP mutations and human fibroblasts derived
from MSP patients. Those cells will be co-stained with SGs marker, VCP, and SQSTM1.
Several E3 ligases have been reported as SGs interactors upon virus infection. However,
identifying SGs-interacting proteins has been challenging since the assembly/disassembly of SGs
occurs rapidly but the components of SGs can be diverse [139]. Also in our scheme, impaired
VCP activity may disrupt the recruitment of SQSTM1 and other interactors such as E3 ligases to
aberrant SGs. To bypass this, a quantitative experiment with enzyme-catalyzed proximity
labeling such as proximity-dependent biotin identification (BioID) or ascorbate peroxidase
(APEX)-mediated labeling will be performed. The advantage of proximity labeling is that the
labeling process can be done in live cells under physiological conditions within a short period of
time [140]. To identify an interacting E3 ligase, APEX-GFP will be fused with TIA1. This TIA1APEX-GFP plasmid will be expressed in stable isotope labelled-p62-/-MEFs and control MEFs
upon heat shock as well as biotin-phenol and H2O2, while the expression of the plasmid will be
visually confirmed. After cells lysis, biotinylated proteins will be enriched with streptavidin
beads, digested by trypsin, and analyzed by mass spectrometry.
The proximity-labeling can be done in cell type-specific context. Investigating cell typespecific proteomics is important because components of SGs are diverse in a cell-type specific
manner, which may answer a question: why certain tissues such as muscle and CNS are more
vulnerable to MSP-causing mutations than others? One possible answer can be found from two
111

recent studies [138]. These studies successfully applied the proximity-labeling proteomics and
identified SGs-interacting proteins in several cell lines including ALS patient-derived neural
progenitor cells. They confirmed the presence of previously reported PQC factors within SGs in
several cell types. They estimated that up to 20% of components are recruited to SGs in a cell
type-specific or stress-specific manner. Interestingly, neuronal cells contain the most diverse
components enriched with PQC machineries and about 75% of SGs components were not
previously reported as SGs components, suggesting that neuronal cells may need more PQC
factors to tightly regulate its protein homeostasis upon environmental stresses. However, musclespecific proteomic information is still lacking. A systemic approach will broaden but specify our
aspects about how diverse SGs components are in different tissues.
Modulating disaggregase activity i.e. Hsp104 or DNaJB6 may provide a therapeutic
strategy to prevent MSP pathogenesis since aberrant interaction of SGs with misfolded proteins
can be prevented by chaperones [135, 136]. Also, chemically inducing autophagy reduces the
number of SGs in ALS patient-derived iPS cells and iPSC-derived neurons [141]. To test
whether disaggregase prevent the accumulation of SGs, Hsp104 or DNaJB6 can be expressed in
human fibroblast from MSP patients or mouse model expressing MSP-disease causing mutation.
Also, autophagy inducers i.e. Rapamycin can be tested to examine the rescue effect in MSPdisease models.
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Figure 2. Proposed model for SGs homeostasis.
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Figure 3. Expected result
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4.5 Concluding remarks
Life is full of stress. However, cells always find their own ways to reduce their stress level and
keep their own peace. They have developed a sophisticated system to control proteins upon
different stresses. This work has investigated protein homeostasis by focusing on how proteins
are aggregated and degraded (Chapter 2). Also, this work demonstrated that the biology of
protein homeostasis is complex since it is temporally and spatially regulated with RNA
metabolism (Chapter 3). The introduction of a single genetic mutation can disrupt this whole
system but is very unpredictable, suggesting that many future studies should be coming along
from multiple angles. However, understanding of MSP genetics has been paving the way for
researchers to focus on various cellular pathways. More genetic studies together with molecular
studies should be continued to delineate underlying mechanism of MSP.
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